Coronavirus: diagnostikoa eta terapia gizakietan

MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF

Resumen de: US2024309072A1

The present disclosure provides multivalent anti-spike protein binding molecules, comprising multimerization moieties linked to anti-spike protein antigen-binding domains, that specifically bind to RBD regions of SARS-COV and/or SARS-COV-2. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules to treat conditions associated with SARS-COV and SARS-COV-2 infections, such as COVID-19.

Detecting SARS-CoV-2 and Other Infective Agents

Resumen de: US2024310376A1

Described herein are compositions for detecting an antigen, including but not limited to, a SARS-CoV-2 antigen, in a sample using a flow cytometry platform. The use of the flow cytometry platform described herein allows for the detection of one or more antibodies in a sample from a patient.

Wearable Collector for Noninvasive Sampling of Exhaled Breath Biomarkers, Pathogens or Viral Loads

Resumen de: US2024306936A1

Airborne transmission of exhaled virus can rapidly spread by increasing disease progression from local incidents to pandemics. Due to the COVID-19 pandemic, states and local governments have enforced the use of protective masks in common and work areas to minimize disease spread. Here, the function of protective face coverings is leveraged towards COVID-19 diagnosis. A user-friendly, affordable, and wearable adhesive collector was developed. This non-invasive platform is integrated into protective masks towards collecting airborne virus exhaled from individuals' breath over the wearing period. After sampling or collecting, the enriched pathogen can be extracted from the collector for further analytical evaluation. To validate this design, qualitative colorimetric loop-mediated isothermal amplification (LAMP), quantitative reverse transcription polymerase chain reaction (RT-PCR), and antibody-based dot blot assays were performed to detect the presence of SARS-CoV-2. This platform enables easy sampling of current SARS-CoV-2 and other airborne diseases of future pandemics.

REVERSE GENETICS-BASED COMPOSITIONS OF ATTENUATED RECOMBINANT SARS-COV-2

Resumen de: US2024307525A1

Provided here are compositions for a bacterial artificial chromosome-based construct containing a replication-competent recombinant severe acute respiratory syndrome coronavirus-2 (rSARS-CoV-2) genome and methods of making such compositions and uses thereof. The rSARS-Cov-2 provided herein can be attenuated and safely worked with under BLS-2+ conditions.

COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19

Resumen de: US2024307522A1

The present disclosure generally relates to compositions, formulations, methods, and/or uses of nucleic acid vaccines, specifically nucleic acid vaccines (e.g., RNA, mRNA, DNA vaccines) encoding one or more proteins, peptides, fragments or variants thereof of SARS-CoV-2 for the prevention, alleviation and/or treatment and/or prevention of COVID-19, including mitigation of physiologic effects of infection and/or symptoms.

NOVEL CORONAVIRUS VACCINE BASED ON CONTROLLABLE SECRETORY EXPRESSION OF ATTENUATED SALMONELLA, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

Resumen de: US2024307523A1

A coronavirus vaccine based on controllable secretory expression of attenuated Salmonella, a preparation method therefor, and use thereof. The method includes constructing controllable and stable expression plasmids for secretory expression of different antigenic structural domain proteins of the new coronaviruses and their attenuated Salmonella expression strains, and then mixing various attenuated Salmonella antigen-presenting strains that can achieve controllable intracellular secretory expression in antigen-presenting cells. With the aid of a unique secretion system, a variety of different antigenic proteins can be secretory-expressed efficiently in antigen-presenting cells after oral gavaging. The secretory-expressed antigenic proteins can be efficiently processed and presented by the antigen-presenting cells, and finally activate/regulate the immune system to produce more potent antibodies to make the vaccine work.

REMDESIVIR COCRYSTAL, COMPOSITIONS AND METHODS THEREOF

Resumen de: US2024307427A1

Provided is a cocrystals of remdesivir (RDV) composed of a 1:1 molar ratio of RDV and benzoic acid derivative. The benzoic acid derivative can be salicylic acid (SA). The RDV-SA cocrystal are formed by either liquid-assisted grinding or spray-drying, followed by thermal annealing to facilitate cocrystal formation. The RDV-SA cocrystals can be formulated as inhalable dry powders and included in a medicament for use in treatments for influenza viral infections, such as COVID-19. The inhalable RDV-SA cocrystal dry powders is suitable for deep lung delivery, with good dissolution performance.

PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT

Resumen de: US2024309059A1

Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-19.

FOLLICULAR HELPER T (TFH) CELLS SPECIFIC TO SARS-COV-2 VIRUS

Resumen de: US2024309051A1

Follicular helper T cells specific to SARS-COV-2 virus are provided. The present disclosure is based on the finding of public TfhTCR specific to spike (S) protein common to various patients, and has identified for the first time a public TCR specific to the SARS-COV-2 virus and its MHC and antigenic epitopes to promote efficient immune responses, particularly those of B cells that produce neutralizing antibodies. For example, the present disclosure provides a composition containing an epitope specific to SARS-COV-2 virus for inducing a follicular T cell.

NOVEL COMPOUNDS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL COMPLICATIONS OF VIRAL INFECTIONS

Resumen de: US2024307339A1

The present invention relates to a compound of formula (I):as well as a metabolite of the compound of formula (I), pharmaceutical composition comprising the compound of formula (I) or its metabolite, and/or ophioglossum for use in the treatment, prevention and/or alleviation of symptoms of neurological complication(s) of a viral infection disease. The instant compounds, metabolites, pharmaceutical compositions and ophioglossus are particularly useful in the treatment, prevention and/or alleviation of symptoms of neurological complication(s) of a viral infection disease caused by SARS-CoV-2.

ACE2-IgM-Fc FUSION PROTEINS AND USES THEREOF

Resumen de: US2024307512A1

The present disclosure provides ACE2 fusion proteins, comprising multimerization moieties linked to ACE2 moieties, that specifically bind to RBD regions of SARS-COV and/or SARS-COV-2. The present disclosure further relates to the methods of producing the ACE2 fusion proteins, pharmaceutical compositions comprising of the ACE2 fusion proteins, and methods of use of the ACE2 fusion proteins to treat conditions associated with SARS-COV and SARS-COV-2 infections, such as COVID-19.

Fermented Uni-sourced Nanoemulsion of Nigella sativa or Cannabis sativa For Use in Medical, Cosmetic, and Recreational Indications with a Method of Its Production and Use

Resumen de: US2024307474A1

A botanical uni-sourced drug-loaded lipid-based nanoemulsion produced from one single medicinal herb such as Nigella sativa, Cannabis sativa, or Curcuma longa, wherein the herb acts as a comprehensive provider for the bioactive phytochemicals, oil phase, saponin surfactant, co-surfactant, proteins, and carbohydrates to produce the uni-sourced safe, clear, stable lipid-based drug delivery system. The nanoemulsion can be formulated into oral dosage form including nanoemulsion, microemulsion and liposomes, wherein the extraction and emulsification are carried out by the addition of water-soluble organic solvent, wherein the product can be further fermented and esterified for improved stability, wherein Nigella sativa uni-sourced nanocompositions are used as first-in-class oral formulation to relax coily hair targeting the arrector pili muscle in the hair root, anticancer, anti-tuberculosis, anti-COVID-19; and antiviral treatment, Cannabis nanocompositions are used for medical or recreational purposes, and Curcuma longa is used for nutraceutical and treatment purposes.

COMPOSITIONS OF ANTI-VIRAL PEPTIDES AND/OR COMPOUNDS AND METHODS OF USE THEREOF

Resumen de: US2024307487A1

Broad spectrum antiviral peptides and composition including therapeutically effective amounts of the antiviral peptides along with a pharmaceutically acceptable carrier are provided. The antiviral compositions show a strong broad spectrum antiviral effect, without resulting to viral resistance. The disclosed antiviral compositions are useful for treatment of diseases caused by viral infections, particularly respiratory viruses such as enveloped coronaviruses (SARS-CoV-2, SARS-CoV and MERS-CoV), the pandemic A(H1N1)pdm09 virus, avian influenza A(H7N9) virus, and the non-enveloped rhinovirus.

CORYNEBACTERIUM STRAINS FOR USE IN THE PREVENTION OF A VIRAL INFECTION

Resumen de: US2024307459A1

Corynebacterium strains for use in the prevention of a viral infection Certain enveloped RNA viruses preferably coro-naviruses primarily on the nasal mucosa, then the infection develops into a severe systemic disease. The infection and its course depend on individual susceptibility. The present inventors have found that SARS-COV-2 susceptibility is associated with differences in the overall nasal bacterial community structure. The invention utilizes among others the finding that Corynebacterium spp. has a major role in the prevention of infection and that the bacteria decrease the infection rate via multiple mechanisms. The invention is useful in the treatment and prevention of enveloped RNA virus infections in the upper respiratory tract.

METHOD TO IDENTIFY INDIVIDUALS WITH T CELL IMMUNITY TO SPECIFIC INFECTIOUS AGENTS

Resumen de: US2024310362A1

Methods, devices and kits for rapid identification of individuals previously infected with, or vaccinated for, a bacterial or viral pathogen, such as SARS CoV-2 virus. Pathogen specific memory T cells, such as SARS CoV-2 specific memory T cells, provide indication of prior infection, if detected. Memory T cells are assayed by exposure to specific bacterial and/or viral antigens and then tested for activation by analysis of nucleotide content.

SIGMA RECEPTOR LIGANDS FOR TREATING SARS-COV-2 INFECTION

Resumen de: US2024307370A1

The invention relates to compounds, compositions, and methods of treating viral infection, especially SARS-CoV-2 infection.

Treatment of COVID-19 and Associated Pathologies

Resumen de: US2024307341A1

Unique compositions of matter and formulations useful for treatment of COVID-19. Said formulation function by induction of immune modulation, cellular protection, suppression of inflammation and suppression of viral infection. In one embodiment a formulation consists of therapeutic doses of various nutraceuticals include epigallocatechin gallate (EGCG), sulforaphane, and curcumin. In some embodiments, the preparation are utilized as a adjuvant therapeutic, while in other embodiments said formulation is utilized as a monotherapy. Various delivery mechanisms can be used, including oral, transdermal, sublingual, intrarectal and intravenous administration.

NOVEL OMEGA 3 CARRIER PREPARATIONS FOR INHALATION DRUG DELIVERY FOR TREATING LUNG INFLAMMATION

Resumen de: US2024307302A1

Inflammatory disorders of the lung are induced by COVID-19 disease, asthma, and numerous other disorders. Omega-3 fatty acids (O3FA), particularly docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) or cicosapentaenoic acid (EPA), have known anti-inflammatory and pro-resolving properties. Reduction of lung pathology and inflammation will be accomplished by a mixture incorporating O3FA that is suitable for nebulization using formulas and nebulization apparatus known in the art. The O3FA may be delivered in the form of ethyl esters (EE) or free fatty acid (FEA) oils or non-phosphate-containing glycerolipids or as phospholipids (PL) or as any other form known in the art. The mixture can also be delivered in any of the other forms of inhaled droplet or solids for inhalation known in the art. The patient will inhale for a therapeutically effective period of time to reduce inflammation and improve breathing.

SARS-COV-2 VACCINES

Resumen de: WO2023081936A2

Disclosed herein are vaccine compositions that include SARS-CoV-2 MHC epitope-encoding cassettes and/or full-length SARS-CoV-2 proteins. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.

ANTI-SARS-COV-2 DRUG

Resumen de: EP4431151A1

The present invention relates to a compound represented by formula (I), a salt thereof, a solvate thereof, or a prodrug thereof, and an anti-SARS-CoV-2 drug comprising the same:wherein R¹, R², and R³ are the same or different, and each of them is a hydrogen atom, a halogen atom, a substituted or unsubstituted C_1-6-alkyl group, a substituted or unsubstituted C_1-6-alkoxy group, or -N(R^a)(R^b) (wherein R^a and R^b are the same or different, and each of them is a substituted or unsubstituted C_1-10-alkyl group or a substituted or unsubstituted aryl group; or R^a and R^b, together with an adjacent nitrogen atom, may form a substituted or unsubstituted 5 to 7-membered ring),R⁴ is -N(R^a)(R^b) (wherein R^a and R^b are the same or different, and each of them is a substituted or unsubstituted C_1-10-alkyl group or a substituted or unsubstituted aryl group; or R^a and R^b, together with an adjacent nitrogen atom, may form a substituted or unsubstituted 5 to 7-membered ring),X is a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, or

METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACIDS AND NUCLEASES IN A BODY FLUID AS INDICATORS OF DISEASE

Resumen de: US2024301480A1

Provided herein are methods and compositions for analyzing extracellular (cell-free) nucleic acids and/or nucleases in a body fluid, to identify subjects having a disease or condition associated with a change in the amount of cell-free nucleic acids and/or nuclease activity compared to the amount of cell-free nucleic acids and/or nuclease activity in a healthy subject. The methods and compositions provided herein can be used to identify subjects having a disease such as cancer, or a disease caused by a pathogen, for example, a virus, such as SARS-CoV-2.

ACE2-RECEPTOR ECTODOMAIN FUSION MOLECULES AND USES THEREOF

Resumen de: US2024301381A1

The present invention relates, in general, to polypeptides capable of neutralizing SARS-CoV-2 and providing ACE2 enzymatic activity, and uses of these polypeptides for treating disorders related coronaviral infections (COVID-19) and the accompanying acute respiratory distress syndrome (ARDS) and major organ injuries, and methods of making such molecules.

Compositions that Block Activation of the Sars-CoV-2 Replication and Transcription Complex (RTC) and Methods of Use Thereof

Resumen de: US2024301039A1

The invention provides nanobodies that bind with high affinity to SARS-CoV-2 non-structural protein (Nsp), as well and compositions comprising the identified nanobodies and methods of use thereof to block activation of SARS-CoV-2 viral replication, and for the treatment or prevention of COVID-19.

ANTIBODIES TO SARS-COV-2

Resumen de: US2024301038A1

Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.

NUCLEOCAPSID ANTIGEN IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE

Resumen de: WO2024186803A2

The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 nucleocapsid protein (N-protein) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID- 19 as a booster vaccination, to antibody naive patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary' Fc fusion proteins and pharmaceutical formulations of exemplary' Fc fusion proteins are provided, in addition to methods of use and preparation.

FORMULATIONS COMPRISING STABILIZED SARS-COV-2 PEPTIDES AND USES THEREOF

Resumen de: WO2024187120A1

Disclosed herein are dry powders, anhydrous compositions, and emulsions comprising a peptide that binds to a SARS-CoV-2 spike protein. The dry powders, anhydrous compositions, and emulsions disclosed herein are useful for the treatment and/or prevention of a coronavirus infection.

COMBINATION THERAPIES COMPRISING STABILIZED SARS-COV-2 PEPTIDES

Resumen de: WO2024187121A1

Disclosed herein are methods of treating and/or preventing a coronavirus infection using a peptide that binds to a SARS-CoV-2 spike protein and an additional therapeutic agent. Also provided herein are therapeutic combinations comprising a peptide that binds to a SARS-CoV-2 spike protein and an additional therapeutic agent.

NOVEL CORONAVIRUS PROTECTIVE NASAL SPRAY, AND PREPARATION AND USE THEREOF

Resumen de: WO2024183704A1

A fully human ACE2-Fc fusion protein, a pharmaceutical composition, preparation and kit containing same, and a nasal spray containing the fusion protein. Also provided is a use of the fusion protein for broad-spectrum prevention of coronavirus infections, such as infections with coronavirus SARS-CoV-2 and known and unknown variants thereof, including but not limited to original Hu-1, alpha, beta, gamma, delta, mu, omicron, JN.1, and/or other future strains. Also provided are a method for producing the fusion protein, and a method for using the fusion protein to prevent and/or treat infections with coronavirus SARS-CoV-2 and known and unknown variant strains thereof. Further provided is a use of the fusion protein and the pharmaceutical composition and preparation containing same for preventing the spread of coronavirus SARS-CoV-2 and known and unknown variant strains in infected subjects.

PROTEIN OR MRNA VACCINE AGAINST NOVEL CORONAVIRUS AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2024183687A1

A protein or mRNA vaccine against novel coronavirus and a preparation method therefor and a use thereof. The protein has addition, deletion or substitution of one or more amino acid residues in an amino acid sequence shown in SEQ ID NO: 2. A nucleic acid encodes an S protein mutant. The preclinical animal test data of the mRNA vaccine shows that the mRNA vaccine has a good protection effect against current novel coronavirus mainstream variants of concern (VOCs).

PEARL POLYPEPTIDE FOR IMPROVING ACE2 ENZYME ACTIVITY AND INHIBITING SPECIFIC BINDING OF SARS-COV-2 S PROTEIN AND ACE2, AND USE OF PEARL POLYPEPTIDE

Resumen de: WO2024183115A1

The present invention provides a bioactive peptide derived from a saltwater pearl, wherein an amino acid sequence of the bioactive peptide is Ile-Pro-Ser-Thr-Thr-Pro-Phe-Pro-Ser-Thr-Thr-Val-Ala-Thr-Thr-Thr-Met, and the bioactive peptide is named as an SCOL polypeptide. The active peptide can improve ACE2 enzyme activity by 3.76 times, can be used for preparing a drug for improving ACE2 activity, and can be used for preparing drugs for treating hypertension, resisting heart failure, resisting tissue fibrosis, resisting inflammation, treating type 2 diabetes and complications thereof, and relieving neuropathic pain. The active peptide can specifically bind to ACE2, effectively inhibit the binding of 65% of SARS-CoV-2 S protein and ACE2, and can be used as a retardant to prepare a drug against a coronavirus infection, especially a SARS-CoV-2 resistant drug.

DUAL-AFFINITY PROBES AND SYSTEMS FOR ANALYTE DETECTION

Resumen de: AU2023229713A1

The present document describes a dual-affinity probe comprising an organic or inorganic surface binding peptide and a target-specific capture element, which may bind to various targets, such as pathogens. This document further describes uses of the dual-affinity probe, and kits to determine the presence of and/or quantity of a target in a sample. In particular embodiments, the dual-affinity probe is specific for SARS-CoV-2 (Spike or Nucleocapsid) protein and may be used to determine whether a subject is infected with SARS-CoV-2.

ONE-TO-STOP ATTENUATED SARS-COV-2 VIRUS

Resumen de: AU2023244474A1

The invention relates to a polynucleotide encoding an attenuated SARS-CoV-2 or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons. The polynucleotide may comprise further modifications and may be comprised in an attenuated SARS-CoV-2. The invention further relates to methods for production of the polynucleotide and pharmaceutical products, e.g. for medical use.

ELECTRO-PNEUMATIC INTELLIGENT SYRINGE

Resumen de: US2024299661A1

An electro-pneumatic intelligent syringe includes an injection assembly including a fixing component and a moving component, and a pneumatic assembly including an airway component and a pneumatic component. The electro-pneumatic intelligent syringe can operate intelligently and automatically, which provides equipment support for achieving automatic injection. The electro-pneumatic intelligent syringe can automatically complete the medicine suction and injection operations of the syringe without human control, has high degree of automation, unmanned isolation operation, strong intelligence, safety and efficiency, convenient use, and easy popularization, can avoid direct contact between doctors and patients during the injection process, can effectively reduce the possibility of medical staff being infected by viruses, and is conducive to protecting relevant medical staff, especially suitable for epidemic prevention and epidemic resistance of highly infectious diseases such as corona virus disease 2019 (COVID-19) vaccination and other occasions.

NOVEL REDOX-BASED THERAPEUTIC APPROACH FOR TREATMENT OF CANCER

Resumen de: US2024299401A1

Disclosed herein are compositions and methods for increasing the expression of human SLC7A11. The compositions include a combination of compounds that exhibit anti-proliferative activity against cancer cells. The compositions and methods can be used to treat a subject with cancer. Disclosed are also compositions and methods of treating a coronavirus infection, Zika virus, influenza virus infection, human immunodeficiency virus (HIV), or Rhinovirus.

Oral rinse, nasal spray and methods for prevention of COVID-19 by lowering viral load of COVID-19

Resumen de: US2024299293A1

Compositions and methods are provided for a nasal spray or mouthwash formulation for prevention and amelioration of disease progression caused by a virus infection, the formulation including: an algae derivative; and a buffer. The method effectively bathes the mouth and throat tissues to decrease COVID-19 concentration and functionality; thereby preventing growth and spread of the virus and lower the viral load present in the lungs and in GI tract.

THERAPEUTIC USE OF SARS-COV-2 MRNA DOMAIN VACCINES

Resumen de: US2024299531A1

The disclosure describes coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The RNA vaccines encode domains and subunits of coronavirus.

A DNA PLASMID SARS-CORONA VIRUS-2/COVID-19 VACCINE

Resumen de: US2024299528A1

The present invention relates to DNA vaccine against SARS-Coronavirus-2 (SARS-CoV-2) infection. In particular, the present invention relates to a DNA vaccine encoding the SARS-Coronavirus-2 spike protein for use in prevention or treatment of viral infection in humans and/or animals.The DNA vaccine including the DNA construct has several features in its design that together provide a more safe and broad protection against SARS-Cov-2 strains in humans and animals, e.g. mink, ferrets, pigs and cats. The DNA construct encodes the SPIKE protein derived from the pandemic strain; Wuhan-Hu-1 (MN908947). The sequence is codon optimized for high expression in human and mammalian cells and the DNA construct is inserted in a selected DNA plasmid for eukaryotic in vivo and in vitro expression. The combination of the choice of SARS-COV-2 SPIKE sequence, codon optimization, expression in the new generation eukaryotic expression plasmid with no antibiotic resistance marker (instead the RNA-OUT system is used for safety) and delivery to the very immunogenic skin, results in protection against SARS-COV-2 infection and covid-19 disease.

STEPHANIA CEPHARANTHA-DERIVED ALKALOID-CONTAINING PREPARATION

Resumen de: US2024299481A1

In an embodiment, a Stephania cepharantha-derived alkaloid-containing preparation for treatment of a novel coronavirus infection is provided. According to an embodiment of the present invention, a preparation for treatment of a novel coronavirus infection comprises Cepharanthine, Isotetrandrine, Cycleanine, and Berbamine. A preparation for treatment of a novel coronavirus infection is for treatment of an infection caused by the novel coronavirus mutant strain. According to an embodiment of the present invention, a Stephania cepharantha-derived alkaloid-containing preparation for treatment of a novel coronavirus infection is provided.

DEOPTIMIZED SARS-COV-2 VARIANTS AND METHODS AND USES THEREOF

Resumen de: US2024299533A1

Described herein are modified SARS-CoV-2 variants. These viruses have been recoded, for example, codon deoptimized or codon pair bias deoptimized and are useful for reducing the likelihood or severity of a SARS-CoV-2 variant infection, preventing a SARS-CoV-2 variant infection, eliciting and immune response, or treating a SARS-CoV-2 variant infection.

ANTIVIRAL AGENTS FOR PREVENTION OR TREATMENT OF PATHOLOGIES CAUSED BY ALPHA- AND/OR BETA-CORONAVIRUSES

Resumen de: US2024299442A1

Ester and sulfated derivatives of hyaluronic acid are described for use in the prevention and treatment of the initial stage of SARS-CoV-2 disease.

Use of Inosine in Preparing Drug For Treatment of Corona Virus Disease 2019

Resumen de: US2024299436A1

Use of inosine in preparing a drug for the treatment of coronavirus disease 2019 (COVID-19), where a formulation of the drug includes one or more selected from the group consisting of tablets, capsules, oral liquid preparations, emulsions, and injections. Inosine can reduce level of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) induced interleukin-6 (IL-6), alleviate SARS-COV-2 caused inflammatory lung injury, and further increase the percent survival of critically ill patients with SARS-COV-2.

METHODS AND COMPOSITIONS FOR TREATING LONG COVID-19

Resumen de: US2024299430A1

The invention provides methods of treating long COVID in a patient in need thereof, comprising administering to said patient a composition comprising a therapeutically effective amount of at least one human milk oligosaccharides, wherein such treatment reduces or improves at least one sign or symptom of long COVID.

SAMPLE LYSIS REAGENT COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF

Resumen de: US2024302370A1

Methods of utilizing sample lysis reagent compositions in the handling of samples containing viruses, such as (but not limited to) severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), are disclosed. Kits containing the sample lysis reagent compositions are also disclosed.

METHOD FOR DETECTION OF SARS-CoV-2 MUTATIONS

Resumen de: US2024301520A1

Disclosed herein is a method for detecting SARS-CoV-2 mutations in a sample comprising a nucleic acid molecule. By the method, rapid detection can be made of SARS-CoV-2 variants that has changed in viral characteristics (e.g., infectivity, mortality, vaccine effect, therapeutic effect, etc.), thus early preventing and promptly coping with the spread of infection of SARS-CoV-2 variants.

SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS

Resumen de: US2024025860A1

Provided herein are compounds, pharmaceutical compositions, and methods for treating a SARS-CoV-2 infection.

PHARMACEUTICAL COMPOSITION, ITS USE AS A DRUG AND NEW COMPOUNDS, ESPECIALLY FOR TREATING SARS-COV-2 INFECTION

Resumen de: AU2022381706A1

The present invention relates to a compound comprising a compound having formula (I) wherein R

IMMUNOGENIC CONSTRUCTS AND VACCINES FOR USE IN THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF DISEASES CAUSED BY SARS-COV-2

Resumen de: AU2022381515A1

This invention relates to immunogenic constructs, such as polynucleotides, polypeptides and multimeric proteins and to antigenic units and to pharmaceutical compositions/vaccines comprising such immunogenic constructs or antigenic units, which are useful for the prophylactic and therapeutic treatment of diseases caused by severe acute respiratory coronavirus 2 (SARS-CoV-2), as well as methods for producing and using the immunogenic constructs, antigenic units and pharmaceutical compositions/vaccines.

COMPOSITION FOR TREATMENT AND PREVENTION OF COVID-19

Resumen de: AU2022383505A1

The present disclosure provides pharmaceutical compositions comprising antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 the prevention and treatment of Coronavirus Disease 2019 (COVID-19) in a subject.

COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION METHOD THEREOF

Resumen de: EP4427745A1

Increasingly, infectious diseases due to viruses, bacteria, fungi and other contact-transmissible microorganisms, droplets and/or aerosols, are acquiring greater importance due to globalisation and the ease of dissemination between very distant countries. A characteristic example is the Influenza A pandemic in 2009 and the SARS pandemics due to the SARS-Cov virus in 2003 and the COVID-19 pandemic due to the SARS-CoV-2 virus in 2020. To combat infections that may occur by contact, or by aerosolised drops (including those surfaces contaminated with infectious agents), a wider palette of antimicrobials and virucides is required. The present invention resolves this problem for viral infections with the use of a low toxicity surfactant from the group of trimethylammonium methyl sulfates.

Fusion peptide inhibitors of human coronavirus 229E

Resumen de: US11939354B1

Fusion peptide inhibitors of human coronavirus 229E are provided. The fusion peptide inhibitors of HCoV-229E include peptide #121 (SEQ ID NO: 2: HVLGDISGINASVVQIQKEIDRLNEVAKNLHESLIYLQE), and peptide #125 (SEQ ID NO: 3: HRLRQIRGIRARVVQIQKEIWRLNEVAKLLNESLIYLQE). The fusion peptide inhibitors of HCoV-229E may be administered to a subject in need thereof to inhibit or prevent HCoV-229E cellular entry or infection with HCoV-229E. The fusion peptide inhibitors of HCoV-229E may also be used in HCoV-229E inhibition assays.

PREPARATION AND APPLICATION OF UNIVERSAL VACCINE AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 MUTANTS FOR C-TERMINAL RECEPTOR BINDING DOMAIN

Resumen de: NL2038235A

The present invention belongs to the technical field of biology, and specifically relates 11) a preparation and application of a universal vaccine against severe acute respiratory syndrome coronavirus—2 (SARS—CoV—Z) mutants for a c—terminal receptor binding domain (RBD). Specifically, an application of a nucleotide sequence shown in SEQ ID NO:2 or an amino acid sequence shown in SEQ ID NO:l in the preparation of a vaccine against SARS—CoV—Z is designed. The vaccine designed by the present invention has certain immunogenicity and the produced antibodies have the broad spectrum, which can produce a neutralizing effect on newly emerging variant strains such as Omicron, suggesting that the vaccine may have protective efficacy on various variant strains, and indicating that the vaccine has the potential as a universal vaccine against SARS—CoV—Z.15

METHODS OF TREATING FIBROSIS

Resumen de: WO2024182483A1

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.

ENCAPSULATED LIPOSOMAL NANOFORMULATIONS

Resumen de: WO2024182528A2

Disclosed herein are liposomal compositions including a fatty acid and acetate salt. The compositions are effective to treat and prevent viruses, including SARS-CoV-2 and RSV.

GLYCAN MODIFIED SARS-COV-2 GLYCOPROTEIN NANOPARTICLES AND METHODS OF USE THEREOF

Resumen de: WO2024182700A2

Disclosed herein are glycan-coated spike glycoprotein immunogens, engineered nanoparticle vaccines comprising glycan-coated spike glycoprotein immunogens and methods of use thereof for SARS-CoV-2 vaccines.

COVID-19 TESTING METHOD

Resumen de: WO2024181522A1

Provided is a COVID-19 testing technology whereby it becomes possible to determine the risk of increase in severity of COVID-19. The COVID-19 testing method comprises: (1A) a step for detecting an expression product of at least one gene (gene 1A) selected from the group consisting of PLD4, SLC2A6, CPED1, BIRC3, NT5C3A, EVL, BATF3, CSF1R, ZBP1, TPPP3, IL3RA, GBP5, GPBAR1 and SLAMF7 in intermediate monocytes and/or non-classical monocytes in a biological sample collected from a subject; and/or (1B) a step for detecting an expression product of at least one gene (gene 1B) selected from the group consisting of HERC5, GBP4 and SAMD9 in Naive B cells and/or Memory B cells in a biological sample collected from the subject.

A SYNERGISTIC AQUEOUS NEBULIZATION SUSPENSION FOR MANAGEMENT OF INFECTIOUS RESPIRATORY DISORDERS AND PROCESS OF PREPARATION

Resumen de: WO2024180569A1

The present disclosure relates to non-antibiotic formulation towards elimination of infectious respiratory disorders. More specifically, the present disclosure is directed to a synergistic aqueous nebulization suspension comprising a combination of Sodium Chloride (NaCl), Magnesium Sulphate (MgSo4), Calcium bicarbonate Ca(HCO3)2, Potassium Chloride (KCl), Iodine (I2) / Hypoiodous acid, Aluminium Nanoparticle (Gamma Al2O3) having Particle size 5-50 nm, Glyoxylic acid, Malonic acid, Succinic acid in a therapeutically effective amount that synergistically show activity against infectious diseases that affect the respiratory system including Tuberculosis and SARS-CoV-2, and to a process of preparation thereof.

MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF

Resumen de: WO2024182455A2

The present disclosure provides multivalent anti-spike protein binding molecules, comprising multimerization moieties linked to anti-spike protein antigen-binding domains, that specifically bind to RBD regions of SARS-CoV and/or SARS-CoV-2. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.

COMPOSITIONS FOR TARGETING EXTRACELLULAR VESICLE TRAFFICKING AND METHODS THEREOF

Resumen de: WO2024182745A2

The disclosure relates to human cells and human cell lines comprising a genetic construct, wherein the genetic construct comprises a SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the spike gene, the envelope gene, the membrane gene or a combination thereof, and methods of making the human cells and human cell lines. The disclosure also includes methods of identifying an agent that inhibits release of extracellular vesicles, wherein the extracellular vesicles comprise SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the spike gene, the envelope gene, the membrane gene or a combination thereof.

MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF

Resumen de: WO2024182451A2

The present disclosure provides multivalent anti-spike protein binding molecules. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules, e.g., to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.

COMPOSITION CONTAINING OCTENIDINE, FOR ANTIVIRAL TREATMENT

Resumen de: WO2024179785A1

The present invention relates to the medical-pharmaceutical field of the treatment or therapy of viral infections or virus diseases, more particularly COVID-19. The present invention particularly relates to an active substance and to a (pharmaceutical) composition for use in such a treatment or therapy containing said active substance.

COMPUTER IMPLEMENTED METHOD FOR PREDICTING A MONOCLONAL ANTIBODY SPECIFIC FOR A CERTAIN ANTIGEN OF A PATHOGEN

Resumen de: WO2024180402A1

The present invention refers to a computer implemented method used to identify in an early phase the affinity of a protein-protein contact on the basis of multiple parameters such as the chemical bond affinity, of the interaction of the residues of contact antibody-protein, of the physical-chemical properties of the interactions. In particular, it is able to predict which clinically available monoclonal antibody is more capable of neutralizing a new emerging variant of pathogen such for example Sars Cov-2.

ACE2-IgM-Fc FUSION PROTEINS AND USES THEREOF

Resumen de: WO2024182370A1

The present disclosure provides ACE2 fusion proteins, comprising multimerization moieties linked to ACE2 moieties, that specifically bind to RBD regions of SARS-CoV and/or SARS-CoV-2. The present disclosure further relates to the methods of producing the ACE2 fusion proteins, pharmaceutical compositions comprising of the ACE2 fusion proteins, and methods of use of the ACE2 fusion proteins to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.

PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING SARS-COV-2 ANTIGENS AND METHODS OF USE

Resumen de: US2024293459A1

This disclosure provides for peptides useful for vaccination and other applications, engineered T cell Receptors (TCRs), cells comprising the peptides and TCRs, and methods of making and using the peptides and TCRs. The current disclosure relates to TCRs that specifically recognize SARS-Cov-2 HLA-A2 restricted peptide from membrane glycol-protein (MGP), MGP-65: FVLAAVYRI (SEQ ID NO:22).

BOVINE COLOSTRUM DERIVED ANTIBODIES AND USES THEREOF

Resumen de: US2024293539A1

A method to produce immunoglobulin preparations against viral infection in humans spreading via respiratory route is provided. The method comprises the steps of immunizing dairy cows during a third trimester of at least a first gestation period with antigen proteins derived from at least one virus strain, collecting hyperimmune bovine colostrum comprising immunoglobulins effective against the antigen protein of various strains of the virus, preparing whey from the colostrum, isolating the immunoglobulin molecules from the whey, and preparing an immunoglobulin preparation for use as an intranasal treatment. One aspect of the invention is to produce SARS-CoV-2 spike protein specific hyperimmune bovine colostrum comprising a high concentration of anti-SARS-CoV-2 antibodies. An intranasal delivery system for diminishing risk of SARS-CoV-2 infections in humans is provided.

REPLICATION-COMPETENT ADENOVIRUS TYPE 4 SARS-COV-2 VACCINES AND THEIR USE

Resumen de: US2024293532A1

A replication-competent adenovirus type 4 (Ad4) modified to express the SARS-COV-2 spike protein is described. The genome of the recombinant Ad4 is modified to have a deletion of at least a portion of the adenovirus E3 region to accommodate insertion of the spike protein coding sequence. Administration of the recombinant Ad4 to the upper respiratory tract elicits mucosal immunity, which is important for protection against SARS-COV-2 infection and for preventing transmission of the virus.

INACTIVATED SARS-COV-2 VIRUS VACCINE

Resumen de: US2024293531A1

Described herein are SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

RECOMBINANT MEASLES VIRUS

Resumen de: US2024293533A1

The present invention provides a recombinant measles virus useful as a live vaccine against COVID-19 and a vector used for production of the recombinant measles virus. That is, the present invention relates to a recombinant measles virus having a gene encoding a protein of the coronavirus SARS-COV-2 inserted between the N gene region and the P gene region in a measles virus genome; the recombinant measles virus in which the protein is a spike protein of SARS-COV-2 or a partial protein thereof; and a DNA in which a gene encoding a protein of SARS-COV-2 is inserted in a region ranging from the 1,686th base to the 1,694th base of a base sequence set forth in SEQ ID NO: 2.

CORONAVIRUS GLYCOSYLATION VARIANT VACCINES

Resumen de: US2024293534A1

The disclosure provides SARS-CoV-2 mRNA vaccines, comprising a double proline mutation at positions K986 and V987, and an additional substitution D428N that introduces an N-glycosylation site, as well as methods of using the vaccines and compositions comprising the vaccines.

METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING A DISEASE OR A CONDITION

Resumen de: US2024293354A1

The invention relates to a method and a composition for treating or preventing an inflammatory, autoimmune and/or Coronavirus disease and/or symptom. In some embodiments, the-invention relates to a method or a composition for treating or preventing a Coronavirus disease-19 (COVID-19) as well as preventing and curing long term COVID-19 side effects. The composition is a herbal mineral composition or includes the active ingredients that may be found in herbs together with a mineral.

METHODS AND COMPOSITIONS FOR TREATMENT OF COVID-19

Resumen de: US2024293384A1

A drug scaffold, MIND-4 and MIND4-17, and derivatives thereof, can be used to treat and prevent infection by SARS-CoV-2 that causes COVID-19, other coronavirus infections, and the associated immune and inflammatory responses. Surprisingly, these compounds inhibit the tubulin network of virally-infected cells, and inhibit viral replication. The compounds and methods described herein are useful in the inhibition of viral replication in a virally-infected cell. The cell can be a cell infected with severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), or infected with another SARS coronavirus, or SARS-like coronavirus.

PROTEASE INHIBITORS AND METHODS OF USE

Resumen de: US2024293380A1

Disclosed herein are compounds that inhibit the 3C-like protease of SARS-CoV-2. Also disclosed herein are pharmaceutical compositions comprising the compounds, and methods of using the compounds, e.g., in a method of treating a viral infection, such as a coronavirus infection.

SARS-CoV-2 immunodominant peptide constructs and uses thereof

Resumen de: AU2024205749A1

Abstract Provided herein are methods and compositions for the treatment and/or prevention of COVID-19 through the induction of an immune response against identified SARS-COV- 2 immunodominant peptides.

COMBINED PLANT COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS INCLUDING COVID-19

Resumen de: AU2024205781A1

COMBINED PLANT COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS INCLUDING COVID-19 Abstract The present invention is directed to a compound herbal composition for treatment of or prevention of COVID-19 or other viral infections, and/or treatment of or prevention of one or more of medical conditions resulting from COVID-19, comprising: Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras, Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, and Prunus persica. Further herbal extracts can also be added to this base composition, including Tetradium ruticarpum, Alpinia oxyphylla, Cullen corylifolium, Cornus officinalis, Scutellaria baicalensis, Forsythia suspensa, Dolichos lablab, Coix lachryma-jobi, Agastache rugosa, Myristica fragrans, Cinnamomum cassia, Zingiber officinale, Foeniculum vulgare, Zanthoxylum bungeanum, Astragalus membranaceus, Chrysanthemum indicum, Taraxacum mongolicum, Viola yedoensis, Begonia fimbristipula, Scaphium scaphigerum, Houttuynia cordata, Gardenia jasminoides, Nelumbo nucifera, Lophatherum gracile, Dioscorea oppositifolia, Amomum villosum, Cornus officinalis and Euryale ferox.

DEVELOPMENT OF AN INNOVATIVE INHALATION FORMULATION OF NAFAMOSTAT MESYLATE FOR THE MANAGEMENT OF COVID-19

Resumen de: US2024293350A1

The development of innovative inhalation formulations and preparation methods are provided to be used in the prophylaxis of COVID-19-related mortality from a broad-spectrum serine protease inhibitor NM, which has a potent anti-viral and anti-inflammatory potential. A drug for the infection treatment of SARS-COV-2, Influenza A, Influenza B and NL63 viruses includes the drug substance Nafamostat mesylate, which is a serine protease inhibitor in its inhalation form.

INFORMATION PROVISION METHOD FOR EXAMINING ACTIVE IMMUNITY BY USING PRODUCTION OF NEUTRALIZING ANTIBODIES AND INTERFERON GAMMA

Resumen de: US2024295551A1

The present invention relates to an information provision method for examining active immunity. The present invention comprises (a) preparing a plurality of biological samples; (b) preparing a first reagent containing a vaccine antigen against SARS-CoV-2 or a protein antigen expressed by the vaccine, and a second reagent containing a protein derived from SARS-CoV-2 other than the antigen contained in the first reagent; c) preparing a plurality of mixed samples by mixing the biological samples with the reagents; d) preparing a plurality of detection reagents including a conjugate containing a signal generating means and an anti-interferon gamma antibody; (e) preparing a plurality of analyte samples by adding the detection reagent to the mixed sample; and (f) loading the analyte samples into a plurality of lateral flow cartridges and measuring signals from the cartridges using a signal detector.

ASSAY FOR SARS-CoV-2 INFECTION OF VULNERABLE HUMAN CELLS

Resumen de: US2024295544A1

Provided herein are methods and compositions useful for identifying compounds that can inhibit SARS-CoV-2 infection or the effects thereof, especially in cardiomyocytes (CMs), which are highly infectible by SARS-CoV-2 corona viruses.

Reagents, Pharmaceutical Formulations, and Methods for Treating and Preventing Viral Infection

Resumen de: US2024293501A1

This invention provides reagents, pharmaceutical formulations comprising such reagents, and methods for preventing and treating viral infections, specifically coronavirus infections, and in particular infections in humans with COVID-19.

CROSS-REACTIVE ANTIBODIES RECOGNIZING THE CORONAVIRUS SPIKE S2 DOMAIN

Resumen de: US2024294611A1

Provided herein are antibodies and antibody fragments that bind to the S2 domains of SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins. Methods of using these antibodies in in vitro methods are provided. Methods of using these antibodies in vivo to treat or prevent SARS-CoV-2 infections are also provided.

CROSS-NEUTRALIZING SARS-COV2 ANTIBODIES

Resumen de: US2024294613A1

The present invention provides for cross-neutralizing SARS-COV2 antibodies. The antibodies can be used to treat SARS-CoV2 and variants thereof.

A RECOMBINANT CONSTRUCT FOR SCREENING DRUGS AGAINST SARS-COV-2 SPIKE PROTEIN

Resumen de: AU2022379143A1

Trypsin/trypsin-like proteases have been reported to be facilitating SARS-CoV-2 entry into host cells. Spike has protease cleavage sites between the S1 and S2 domains. Cleavage property of proteases can be used to design drug screening assays meant for screening antiviral candidates against spike cleavage. In the claimed invention we have developed a proof-of-concept assay system for screening drugs against proteases which cleave spike between S1 and S2. We designed a fusion substrate protein containing a reporter protein, the protease cleavage site between S1 and S2 and a cellulose binding domain. The substrate protein can be immobilized on cellulose due to the presence of cellulose binding domain (CBD). When proteases cleave the substrate, CBD remains bound to cellulose and the reporter protein is dislodged. The released reporter can be used as read out of protease activity.

ANTIVIRAL ANTISENSE OLIGONUCLEOTIDE

Resumen de: EP4424827A1

The present specification provides an antisense oligonucleotide or a pharmaceutically acceptable salt or hydrate thereof targeting a particular region in genomic RNA of SARS-CoV-2, a pharmaceutical composition comprising the antisense oligonucleotide or the pharmaceutically acceptable salt or hydrate thereof, etc.

SARS-COV-2 PROLIFERATION INHIBITOR

Resumen de: EP4424177A1

An object of the present invention is to provide a novel agent for inhibiting proliferation of SARS-CoV-2 and a novel agent for preventing onset of COVID-19. According to the present invention, there is provided an agent for inhibiting proliferation of SARS-CoV-2 comprising a lactic acid bacterium as an active ingredient. Also, according to the present invention, there is provided an agent for preventing onset of COVID-19 comprising a lactic acid bacterium as an active ingredient. The lactic acid bacterium which is the active ingredient of the present invention is preferably Lactococcus lactis subsp. lactis. The agent of the present invention is preferably in the form of a food composition.

MONOCLONAL ANTIBODIES SPECIFIC FOR SARS-COV-2 RBD

Resumen de: WO2023072904A1

The present invention relates to monoclonal antibodies binding to the Receptor Binding Domain of the Spike protein of SARS-CoV-2 virus, nucleic acids encoding said antibody, host cells producing the same, compositions and kits comprising said antibodies, method of detecting SARS-CoV-2 virus in a sample comprising using said antibodies and methods of using said antibodies in immunoassays.

METHODS FOR THE DIAGNOSIS AND TREATMENT OF CYTOKINE RELEASE SYNDROME

Resumen de: EP4424711A2

The invention relates to methods and pharmaceutical compositions for the treatment of Cytokine Release Syndrome (CRS). The invention also relates to methods for the diagnosis of patients suffering from Cytokine Release Syndrome.The inventors investigate iron homeostasis and the role of CD44-mediated iron endocytosis in the severe inflammatory response and Cytokine Release Syndrome, particularly in SARS-CoV-2 patients. The inventors demonstrate that during activation of M1 macrophages, iron endocytosis is upregulated in a CD44-dependent manner and that CD44 protein levels increase. This effect is specific to M1 macrophages, whereas levels of the canonical iron endocytosis protein TfR1/CD71 remain unchanged. In the present invention, the inventors provide in vitro evidences towards a direct role of CD44-mediated iron endocytosis in the severe inflammatory response such as Cytokine Release Syndrome observed in SARS-CoV-2 patients. Thus, the present invention relates to an antagonist of CD44/Hyaluronic Acid pathway for use in the treatment of cytokine release syndrome in a subject in need thereof, particularly severe COVID-19-related cytokine release syndrome.

Compositions and methods for covid-19 treatment

Resumen de: AU2023213185A1

Provided herein are compositions for use in treatment fibrosis and in treatment of COVID-19, preferably moderate COVID-19, comprising Compound (1), or a pharmaceutically acceptable salt thereof. Also provided herein are methods for treatment of COVID-19, preferably moderate COVID-19 comprising administering to a patient in need thereof an amount of between 10 mg/day and 30 mg/day, of Compound (1).

A live attenuated sars-cov-2 and a vaccine made thereof

Resumen de: AU2022435931A1

The invention relates to a polynucleotide encoding a) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; and/or b) at least one non-structural SARS-CoV-2 protein selected from the group consisting of non-structural protein (7), non-structural protein (8), non-structural protein (9), non-structural protein (10), non-structural protein (11), non-structural protein (12), an endoribonuclease, and a 2'-O-methyltransferase, wherein the polynucleotide comprises or consists of at least one sequence part comprising codon-pair deoptimizations in comparison to the SARS-CoV-2 genome. The invention further relates to a live attenuated SARS-CoV-2 comprising this polynucleotide, to a vaccine comprising this live attenuated SARS-CoV-2, as well as to associated methods.

-19 CoVID-19 NUCLEOCAPSID ANTIGEN ANALYTICAL IN-VITRO DIAGNOSTIC KIT FOR FLUORESCENT QUANTITATIVE ANALYSIS USING NASOPHARYNGEAL NASAL AND SALIVA SPECIMEN

Resumen de: KR20240131038A

본 발명은 진단키트를 구성하는 구성 요소 중 버퍼 내에 소량의 계면활성제 및 타액과 비강도말의 점성을 완화해줄 완충제가 있는 버퍼 내 형광염료가 접합된 특이항체가 표적물질과 결합하여 샘플패드에 점적하고 니트로 셀룰로스 다공성 멤브레인을 지나면서 표적 물질과 멤브레인에 분주된 특이항체와 샌드위치 형식의 반응하여 형광 정량 분석이 가능하도록 한 형광 정량분석 체외 진단키트에 관한 것으로, 특히 코로나19 감염여부를 확인하기 위해 사용된 기존 분자진단기반 PCR 검사와 달리 형광 면역 분석 방법을 사용하여, 완충제 및 계면활성제가 들어있는 용액과 비강도말 및 타액과 같은 점성이 높은 검체와 섞은 뒤 진단 키트에 점적하고, 형광 분석 기기를 이용하여 정량 분석하는 방법으로서, 비인두도말의 검체 채취 과정에 발생하는 고통 및 불편함 해소와 타액 및 비강도말의 높은 점성 문제를 해소하여 키트의 측방유동을 안정화할 수 있는 효과가 있을 뿐만 이니라, 기존의 비인두도말에서만 측정하는 코로나19 뉴클레오캡시드 항원을 비강도말 혹은 타액에서 짧은 시간에 정량 진단하여 의료진이 코로나19 감염 여부를 판단할 수 있게 보조적인 역할을 해줄 수 있는 코로나-19 뉴클레오캡시드 항원 형광 면역 정�

METHODS AND COMPOSITIONS BASED ON LONGITUDINAL STUDIES

Resumen de: US2024288440A1

The present application relates to infectious diseases, pathogenic organisms or pathogenic antigens, and the immune responses that are the body's first line of defense thereto. The application enables medical protocols and products inter alia for treating or preventing or limiting the dissemination of an infectious disease. Methods and compositions are disclosed which employ dIgA for assessing functional immune responses to a pathogen, and in prophylactic or therapeutic compositions. In particular embodiments, the methods and compositions enhance the armamentarium for those charged with managing infectious diseases and populations exposed to highly transmissible and potentially debilitating or fatal pathogens such as those causing epidemics. One particular infectious disease is COVID-19 caused by the virus SARS-COV-2.

ANTIBODY AGAINST NUCLEOCAPSID PROTEIN OF SARS-COV-2

Resumen de: US2024288429A1

The purpose of the present invention is to provide an antibody that enables simple, rapid and sensitive detection of SARS-COV-2, i.e., the causative virus of COVID-19 while suppressing nonspecific reactions, and an immunological detection method and a kit comprising the antibody. By using an antibody that binds to the nucleocapsid protein of SARS-COV-2 or an antibody fragment thereof, in particular, an antibody that recognizes a specific region of the protein or an antibody fragment thereof, provided are a specific and sensitive immunological detection method and kit, in particular, a detection method using a sandwich method such as an immunochromatography method or ELISA method, as well as immunochromatographic test strip containing the antibody and a kit containing the test strip.

ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO NUCLEOCAPSID PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 OR FRAGMENT THEREOF, AND USE OF SAID ANTIBODY OR SAID FRAGMENT

Resumen de: US2024288427A1

Provided are an antibody or fragment thereof specifically bindable to the NTD or CTD of the N protein of SARS-CoV-2, and use of the antibody or fragment thereof. An antibody or fragment thereof specifically bindable to the amino acid sequence of SEQ ID NO: 1 or 2 is disclosed.

MODIFIED PIV5 VACCINE VECTORS: METHODS OF MAKING AND USES

Resumen de: US2024287544A1

A CVB viral expression vector comprising a PIV5 W3A viral genome that contains mutations at amino acid residue S157 or S156 in the P/V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) to phenylalanine (F) or asparagine (N) and wherein the SH gene has a deletion of the SH open reading frame or a deletion of an entire SH gene transcript unit. The CVB viral expression vector wherein the vector expresses a heterologous polypeptide comprising a SARS-CoV-2 spike (S), and/or nucleocapsid (N) and/or membrane (M) proteins, RSV fusion protein (F) or other antigens.

CIRCULATING LEVELS OF ENDOTHELIAL MICRORNA PREDICT NEW-ONSET DIABETES IN COVID-19 AND LONG COVID

Resumen de: US2024287608A1

Provided herein are compositions and methods for identifying COVID-19 subjects at risk for developing diabetes.

MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF

Resumen de: US2024287162A1

The present disclosure provides multivalent anti-spike protein binding molecules. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules, e.g., to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.

ANTIBODY AGAINST CORONAVIRUS

Resumen de: US2024287161A1

Provided is a human antibody against a spike protein of coronavirus, in particular, against a protein in an extracellular region or a receptor-binding domain.

ETHACRYNIC ACID DERIVATIVES AS INHIBITORS OF MPRO PROTEASE AND SARS-COV-2 REPLICATION

Resumen de: US2024287003A1

A novel compound of formulae (I) or (II), to the use thereof as a drug, particularly for the treatment of SARS-COV-2, for the treatment of COVID-19 disease and any diseases related to beta-coronaviruses, and for the in vitro application thereof in order to study the interaction with Mpro protease.

METHOD AND SYSTEM FOR COMPUTER-AIDED TRACKING OF A PROCEDURE TO BE CARRIED OUT BY A PERSON

Resumen de: US2024290476A1

The disclosure relates to a method and a system for computer-aided tracking of a procedure to be carried out by a person, in particular a production procedure or test procedure, for example for a virus detection test, preferably for carrying out an antigen test for SARS-CoV-2. The disclosure also relates to a method and system for computer-aided validation of a procedure carried out by a person and tracked by computer. The disclosure also relates to a method and system for setting up a person profile for use in one of the aforementioned methods and systems. The disclosure also relates to a computer program product.

AN EPITOPE ORIGINATING FROM SARS-COV-2 N PROTEIN, AN ANTIGEN CONTAINING THE EPITOPE, USES THEREOF AND A METHOD FOR DETECTING DISEASE CAUSED BY CORONAVIRUS

Resumen de: WO2024177525A2

Epitopes originating from SARS-CoV-2 N protein, vaccine antigens specific for SARS-CoV-2 containing the epitopes useful in the treatment or prevention of disease caused by coronavirus as well as a method for detecting disease caused by coronavirus, in particular COVID-19, especially with an acute course, are disclosed.

SARS-CoV-2 NEUTRALIZING ANTIBODIES

Resumen de: WO2024175802A2

The present invention relates to antibodies or antigen-binding fragments thereof against SARS- related coronavirus, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, kits comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof, the pharmaceutical compositions and the kits for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus. The present invention further relates to methods of treating, preventing or reducing the severity of an infection with a SARS-related coronavirus, and to nucleic acids encoding such antibodies or antigen-binding fragments thereof, expression vectors comprising such nucleic acids, host cells comprising such nucleic acids or expression vectors, and methods for the production of such antibodies or antigen-binding fragments thereof.

EXPANDING AND IMPROVING NANOBODY REPERTOIRES: TARGETING SARS-COV-2

Resumen de: WO2024178232A2

Provided are anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) VHH antibodies, and methods of making and using the VHH chain antibodies.

CRIPPLED CORONAVIRUS: 5'-POLYU TARGETED OLIGO PREVENTS DEVELOPMENT OF INFECTIOUS VIRIONS

Resumen de: WO2024178065A2

The present disclosure provides compositions and methods for treating and detecting coronavirus infection, and in particular, provides compositions and methods for treating and detecting SARS-CoV-2 infection. The present disclosure also relates to the production of compositions for treating and detecting coronavirus infection, and in particular, to the production of compositions for treating and detecting SARS-CoV-2 infection.

MULTICISTRONIC VACCINE AND METHODS FOR PRODUCING AND USING THE SAME

Resumen de: WO2024178371A1

The present disclosure provides multi ci str onic vaccines and method for producing and using the same in preventing infection or transmission, or reducing severity of disease caused by influenza and/or SARS-Cov-2 virus in a subject. Multicistronic vaccines of the disclosure can be administered via intramuscular, intranasal, or inhalation route. In one particular embodiments, the disclosure provides a recombinant adenovirus comprising at least two different extraneous oligonucleotides that are capable of stimulating an immune response in a subject. Each of the oligonucleotide independently comprises an oligonucleotide that encodes either influenza or SARS-Cov-2 virus antigens.

ADJUVANTED PROTEIN VACCINES COMPRISING MODIFIED FULL-LENGTH SPIKE PROTEIN OF SARS-COV-2 COMPOSITION AND METHODS OF USE

Resumen de: WO2024177672A1

Disclosed herein are adjuvanted protein vaccines comprising: a non-phospholipid liposome and one or more proteins, wherein the protein is encapsulated within the non- phospholipid liposome, and wherein the protein is selected from: (i) a modified full-length spike protein that generates IgG antibody responses for 120 days after two injections of the adjuvanted protein vaccine, by subcutaneous or intramuscular routes; (ii) a modified spike protein sequence of a coronavirus; (iii) a protein sequence from a coronavirus; and (iv) a protein from an infectious agent that generates IgG antibody responses to proteins after one or two subcutaneous or intramuscular injections. Also disclose herein are modified spike protein sequence containing a modified full-length SARS-CoV-2 spike protein sequence. Methods of use of the vaccines and sequences are also disclosed herein.

METHODS FOR TREATING INFLAMMATORY AND/OR AUTOIMMUNE SYMPTOMS ASSOCIATED WITH BIOLOGIC AND/OR mRNA VACCINE ADMINISTRATION

Resumen de: WO2024176194A1

Methods for treating inflammatory, autoinflammatory or autoimmune symptoms associated with administration of a biologic (e.g., a vaccine) are described herein. Certain methods include treating side effects of mRNA based vaccines such as COVID-19 vaccines.

EG017 OINTMENT

Resumen de: WO2024174962A1

The present invention provides an EG017 semi-solid formulation. By means of adjustment of the type of a fat-soluble matrix, addition of an antibacterial agent, and optimization of a preparation process, the EG017 semi-solid formulation (such as an ointment) can be administrated in an external application mode to treat and/or prevent eye symptoms caused by xerophthalmia, corneal injury and SARS-CoV-2, solving the problem in the prior art of topical administration of EG017 to eyes leading to no noticeable effect.

BISPECIFIC ANTIBODY FOR BROAD-SPECTRUM NOVEL CORONAVIRUS

Resumen de: WO2024174595A1

The present invention provides a bispecific antibody for a broad-spectrum novel coronavirus. The bispecific antibody of the present invention comprises a first targeting domain D1, which targets a first epitope of a SARS-CoV-2RBD domain; and a second targeting domain D2, which targets a second epitope of the SARS-CoV-2RBD domain. The bispecific antibody of the present invention has broad-spectrum neutralizing activity, can effectively neutralize SARS‐CoV‐2 and a variety of SARS‐CoV‐2 novel coronavirus variants having strong infectivity and high harmfulness, and therefore has great application value in prevention, treatment and/or detection of novel coronavirus infection.

PREPARATION METHOD AND APPLICATION OF ULTRA-RAPID AND HIGH-SENSITIVITY MULTICHANNEL NOVEL CORONAVIRUS NUCLEIC ACID RAMAN ANALYSIS CHIP

Resumen de: WO2024174565A1

A preparation method for a multichannel novel coronavirus nucleic acid Raman analysis chip. Firstly, by using a semiconductor nanomaterial self-assembly method, an SERS substrate is constructed on the surface of a hydrophilic substrate as a signal amplification unit; secondly, according to the nucleic acid sequence of a target strain of novel coronavirus, a plurality of virus nucleic acid recognition units having a single base recognition capability are synthesized; thirdly, by using a Raman signal molecule PTCDA as a signal response unit and using TCNQ as a signal reference unit, a ratiometric Raman signal is constructed as a signal output unit for nucleic acid test, so that a rapid novel coronavirus nucleic acid Raman analysis probe is constructed, wherein the probe contains no enzyme and is free of a nucleic acid amplification process; and finally, analysis probes are spatially arranged in sequence for the nucleic acid sequences of different novel coronavirus variant strains, to prepare a multichannel novel coronavirus nucleic acid Raman analysis chip.

IMMUNOGENIC COMPOSITION, USE THEREOF AND PROCESS OF OBTAINING A COMBINED IMMUNOGENIC COMPOSITION AGAINST COVID-19 AND SEASONAL INFLUENZA

Resumen de: WO2024174012A1

The present invention relates to an immunogenic composition that comprises (i) antigens of the inactivated Newcastle virus (NDV) expressing a stabilized form of the spike antigen (HXP-S) of SARS-CoV-2 (NDV-HXP-S); and (ii) antigens of the trivalent vaccine for seasonal influenza, the composition optionally also comprising an adjuvant. Furthermore, the present invention relates to the use of said immunogenic composition for producing a combined vaccine against COVID-19 and seasonal influenza. Additionally, the present invention relates to a method for obtaining said combined vaccine that comprises the following steps: (a) producing the virus and NDV-HXP-S antigen on an industrial scale using the same factory as that used for producing a monovalent seasonal influenza vaccine; (b) producing the monovalent seasonal influenza vaccine; and (c) combining the antigen compositions of steps "a" and "b" with an acceptable pharmaceutical vehicle to create the combined vaccine.

MICROWAVE DISINFECTION PROTOCOL OPTIMISED FOR THE DESTRUCTION/ INACTIVATION OF SARS-COV-2 AND H1N1 VIRUSES

Resumen de: AU2023225212A1

The invention concerns a microwave disinfection device ( 2 ) configured to destroy/ inactivate the SARS-CoV-2 and H1N1 viruses and comprising a microwave irradiation section ( 22 ) configured to : irradiate microwave signals that have an incident electric field amplitude not higher than 6 V/m and frequencies that are included in the 8-10 GHz band and are spaced from each other by a step comprised between 10 MHz and 100 MHz; irradiate the microwave signals at each individual frequency for a time interval comprised between 50 ms and 1 s; and irradiate the microwave signals with duty cycles comprised between 5% and 50%.

ALZ-801 FOR USE IN TREATING A COVID-19 ASSOCIATED NEUROLOGICAL SYMPTOM

Resumen de: AU2023215421A1

Provided herein are methods for reducing p-tau, Abeta40, Abeta42, and/or the p-tau/Abeta42 ratio in subjects using ALZ-801. Also provided are methods of treating conditions associated with elevated levels of p-tau, elevated levels of Abeta40, elevated levels of Abeta42, and/or an elevated p-tau/Abeta42 ratio.

METHODS FOR TREATING INFLAMMATORY AND/OR AUTOIMMUNE SYMPTOMS ASSOCIATED WITH BIOLOGIC AND/OR MRNA VACCINE ADMINISTRATION

Resumen de: US2024285655A1

Methods for treating inflammatory, autoinflammatory or autoimmune symptoms associated with administration of a biologic (e.g., a vaccine) are described herein. Certain methods include treating side effects of mRNA based vaccines such as COVID-19 vaccines.

COMPOUNDS FOR THE TREATMENT OF SARS

Resumen de: US2024285598A1

Disclosed are bis-amide inhibitors of SARS-CoV-2 (CO VID), and methods of using them to treat a severe acute respiratory syndrome.

METHODS OF USING PROBENECID FOR TREATMENT OF CORONAVIRUS INFECTIONS

Resumen de: US2024285561A1

Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or anaolg thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.

PHARMACEUTICAL COMPOSITION COMPRISING LIPASE INHIBITOR FOR TREATMENT OR TREATMENT OF RNA VIRAL INFECTIONS

Resumen de: US2024285557A1

The present invention relates to a therapeutic agent of a lipase inhibitor for a wide spectrum of RNA viral infections in humans and animals. More specifically, the lipase inhibitor can be used as a therapeutic agent for influenza A virus infection, bovine coronavirus infection, porcine epidemic diarrhea coronavirus infection, bovine rotavirus infection, porcine reproductive and respiratory syndrome virus infection, and sapoviral infection and furthermore, can be utilized as a therapeutic agent for various RNA viral infections in humans and animals, such as infections with SARS COV-1, MERS-COV, Zika virus, dengue fever virus, and hepatitis A and C viruses.

COMPOSITIONS FOR AND METHODS OF INHIBITING SARS-COV-2 INFECTION

Resumen de: US2024285552A1

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease 2019 (COVID-19), has emerged as an ongoing global pandemic. Presently, there are no clinically approved vaccines nor drugs for COVID-19. Hence, there is an urgent need to accelerate the development of effective antivirals. One or more members of the 8-Hydroxyquinoline and Benzylamine structural classes inhibited SARS-CoV-2 infection induced cytopathic effect in vitro, inhibited the exopeptidase activity of angiotensin converting enzyme 2 (ACE2), and disrupted the binding between ACE2 and the Spike protein of SARS-CoV-2. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

SUPER M.E.N.

Resumen de: US2024285002A1

Problem: Masks are particularly needed that provide 100% protection from droplet infection by the novel coronavirus, including the eyes, and must enable clear speech, must not fog up transparent sheets or eyeglasses, must be able to be used by women without removing their makeup, and must be able to be worn for long periods of time.Means of Solving the Problems: The invention is designed to increase rigidity by bending flat transparent sheets to improve temperature and humidity, increase internal temperature and humidity to prevent infiltration by viral particles, completely block viral droplets from contacting the eyes, nose and mouth, exhaust exhaled air to prevent fogging of the transparent sheets and eyeglasses, enable clear conversation, prevent women's makeup from being rubbed off, be able to be put in a pocket, enable eating, and support use as an eye mask. The mask is the world's first so-called face shield and has the best performance and the most applications for the novel coronavirus.

PEPTIDES THAT INHIBIT INFECTION BY SARS-COV-2, THE VIRUS THAT CAUSES COVID-19 DISEASE

Resumen de: CA3235784A1

Anti-SARS-CoV-2 ?/?-polypeptides, pharmaceutical compositions containing the same, and methods to inhibit, treat, and ameliorate SARS-CoV-2 infections in mammals, including humans.

Epitope derived from the N protein of the SARS-CoV-2 virus, the antigen containing it, their uses and method of detecting the disease caused by the coronavirus

Resumen de: WO2024177525A2

Epitopes originating from SARS-CoV-2 N protein, vaccine antigens specific for SARS-CoV-2 containing the epitopes useful in the treatment or prevention of disease caused by coronavirus as well as a method for detecting disease caused by coronavirus, in particular COVID-19, especially with an acute course, are disclosed.

PROCYANIDINS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION TRIGGERED BY COVID-19

Resumen de: ZA202213765B

The invention relates to a natural composition for medical purposes and more specifically to a composition comprising procyanidins, for use in the prevention or treatment of endothelial inflammation and/or endothelial systemic dysfunction triggered by Corona virus disease 2019 (COVID-19) including symptomatic post-COVID-19 subjects recovering from COVID-19.

A FAST DIAGNOSTIC KIT FOR DETECTING COVID-19

Resumen de: WO2024170929A1

A diagnostic kit for detecting the CO VID- 19 is developed that the diagnostic kit comprises a positive control, a negative control, at least one reverse transcriptase (RT) enzyme, a a master mix; and a prop primer mix. The disclosed diagnostic kit is capable of detecting an amount of the virus loading in at least three genes simultaneously through an optimal selection of at least three target genes, at least three pairs of probes, and at least three pairs of specific primers for the target genes. This selection make the diagnostic kit detecting the target genes in less than 55 minutes and provide a suitable conditions to prevent progressing the Covid- 19 and serious issues in a patient.

PROTEIN-DERIVED PEPTIDE FOR IMPROVING IMMUNITY AGAINST 2019 NOVEL CORONAVIRUS (2019-nCoV) AND USE THEREOF

Resumen de: US2024279279A1

In some embodiments, the disclosure provides a hazelnut-derived peptide with an inhibitory activity against a 2019 novel coronavirus main protease (2019-nCoV M-pro), including an amino acid sequence of Trp-Trp-Asn-Leu-Asn (WWNLN). In other embodiments, the disclosure provides use of the hazelnut-derived peptide with an inhibitory activity against a 2019-nCoV M-pro in preparation of a drug, a health product, or a food supplementary for inhibiting a 2019-nCoV infection. In further embodiments, the derived peptide WWNLN in the disclosure has a high 2019-nCoV M-pro inhibitory activity, with an inhibition rate of 74.13%±1.93% and a half maximal inhibitory concentration (IC50) value of 6.695 μM. In some embodiments, the derived peptide may be used to prepare drugs, health products, or foods supplementary that inhibit 2019-nCoV infections, and may show desirable application prospects.

PROTECTION SEQUENCE, PRIMER, PROBE, COMPOSITION AND KIT FOR STEADY-STATE RAPID DETECTION OF NOVEL CORONAVIRUS, AND USE THEREOF AND METHOD THEREFOR

Resumen de: US2024279752A1

The present invention uses a lysis protection solution to treat patient samples, and the samples release genes targeting the 2019-nCoV virus. In the lysis protection solution, multiple target genetic loci are effectively identified by a protection sequence to form a compound, making 2019-nCoV RNA more stable and avoiding extracting purified RNA. The enriched 2019-nCoV RNA compound is further subjected to reverse transcription to obtain cDNA. A signal is then amplified for 40 cycles after the product is identified by a specific 2019-nCoV probe.

CORONAVIRUS VACCINE

Resumen de: US2024277830A1

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-COV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

A RESPIRATORY SUPPORT APPARATUS

Resumen de: US2024277966A1

Embodiments of a respiratory support apparatus are disclosed comprising features configured to minimize, reduce or contain aerosols carrying pathogens that can cause diseases such as COVID 19, SARS, MERS, Tuberculosis, or any other infectious diseases. Embodiments of a respiratory support apparatus are also provided configured to at least reduce the amount of oxygen required, during use of the apparatus, from an external oxygen supply such as an oxygen tank or hospital wall supply. Embodiments of such apparatus are provided with means to recirculate expiratory gases, and/or redirect leak flow. Embodiments of such apparatus are provided in which expiratory gases are sucked away from the patient. Embodiments of such apparatus are provided comprising a first flow generator for delivering inspiratory gases, and a second flow generator for removing expiratory gases.

Self-Amplifying RNA-Based VLP Vaccines

Resumen de: US2024277836A1

The present disclosure provides compositions comprising an sa-RNA VLP vaccine (e.g. the VLP vaccine) that is capable of delivering a self-amplifying RNA to a target cell in a patient, and subsequently elicit an immune response in the patient, which immune response is sufficient to prevent or significantly decrease the duration of an infection by an infectious agent, such as SARS-CoV-2.

TREATMENT OF KNOWN AND UNKNOWN VIRAL INFECTION WITH LIPID AGENTS

Resumen de: US2024277740A1

The present invention provides compositions, systems, kits, and methods for treating a subject with a known or unknown enveloped or non-enveloped viral infection (e.g., an unknown virus, RSV, ADV, SARS-CoV2, CHKV, DENV, HSV-1, HSV-2, EBOV, MARV, ZIKV, or a weaponized virus) by administering or providing a composition comprising a lipid agent selected from: a sulfatide, a sulfatide analog, a ceramide, a lipid moiety comprising a ceramide, a sulfoglycolipid, a sulfogalactolipid, a glycosphingolipid, a seminolipid, or a sphingomyelin. In some embodiments, the compositions reduce lung or systemic inflammation in the subject and/or inhibit viral infection. In certain embodiments, the compositions herein are employed to stop a natural pandemic or a biological attack (e.g., with new or weaponized viruses).

DJUVANTED PROTEIN VACCINES COMPRISING MODIFIED FULL-LENGTH SPIKE PROTEIN OF SARS-COV-2 COMPOSITION AND METHODS OF USE

Resumen de: US2024277832A1

Disclosed herein are adjuvanted protein vaccines comprising: a non-phospholipid liposome and one or more proteins, wherein the protein is encapsulated within the non-phospholipid liposome, and wherein the protein is selected from:(i) a modified full-length spike protein that generates IgG antibody responses for 120 days after two injections of the adjuvanted protein vaccine, by subcutaneous or intramuscular routes;(ii) a modified spike protein sequence of a coronavirus;(iii) a protein sequence from a coronavirus; and(iv) a protein from an infectious agent that generates IgG antibody responses to proteins after one or two subcutaneous or intramuscular injections.Also disclose herein are modified spike protein sequence containing a modified full-length SARS-COV-2 spike protein sequence. Methods of use of the vaccines and sequences are also disclosed herein.

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF COVID-19 AND RELATED PATHOLOGIES

Resumen de: US2024277826A1

The invention relates to a method and to a medicament for use in the treatment of COVID-19 and related pathologies, the medicament comprising or interacting with one or more conserved regions of at least 4 consecutive amino acids with a 100% match present in both the SARS-CoV-2 proteome and the human proteome, wherein the one or more conserved regions are preferably selected by: a. identification of one or more conserved regions of at least 4 consecutive amino acids with a 100% match between the SARS-CoV-2 proteome and the human proteome; b. identification of at least one pathway class from a systematic database comprising a plurality of human physiological pathway classes, each class comprising a plurality of human proteins that are functionally related to the said physiological pathway, wherein the said at least one pathway class shares at least one pathology and/or complication of the COVID-19 infection as a result of dysfunction in the said pathway and comprises at least one human protein comprising one or more conserved regions of at least 4 consecutive amino acids that have a 100% match with the SARS-CoV-2 proteome; and c. selecting the said identified one or more conserved regions for the preparation of the medicament. Based on this approach peptides were selected for the treatment of COVID-19 and several pathologies and complications that can occur in the context of COVID-19, but also as a separate disease, pathology, or complication. The invention also relates to a v

COMPOSITIONS AND METHODS FOR DEBULKING VIRUS OR MICROORGANISM LOAD IN THE ORAL CAVITY

Resumen de: US2024277819A1

Compositions and methods for reducing viral load in the oral cavity, particularly Coronavirus such as SARS-CoV-2 and Influenza viral loads are disclosed. Also disclosed are compositions and methods for reducing bacterial or fungal loads in the oral cavity. The compositions comprise a trapping molecule having binding affinity for a protein, glucan, or other molecule on the surface of a virus or microorganism. A carrier appropriate for oral administration, in the form of a chewing gum, long-acting lozenge, or tablet, is further disclosed, to enable easy administration before or after exposure to the infective agent.

SUPPRESSION OF COVID-19 REPLICATION BY COVID-19 ENTRY INHIBITORS

Resumen de: US2024277730A1

The present invention relates to compounds, compositions, and methods, for treating viral infections. In particular, entry inhibitor compounds are disclosed for treatment of coronavirus infections, including SARS-COV-1 and SARS-COV-2 infections. The compounds bind to the interface of a SARS-COV-2 spike protein receptor binding domain (RBD) and a host cell ACE-2 receptor. The entry inhibitor compounds show antiviral activity, favorable kinetics, and temporally act at the entry of SARS-COV-2 infection. In embodiments, the compounds are used as medicaments for the inhibition of viral replication including SARS-COV-1 and/or SARS-COV-2 replication, for the treatment or prophylaxis of viral infections including SARS-COV-1 and SARS-COV-2 infections, and/or for the treatment or prophylaxis of an illness due to SARS-COV-1 and SARS-COV-2 infections.

A RAPID MULTIPLEX RPA BASED NANOPORE SEQUENCING METHOD FOR REAL-TIME DETECTION AND SEQUENCING OF MULTIPLE VIRAL PATHOGENS

Resumen de: US2024279751A1

Methods for the rapid and accurate detection and characterization of a viral nucleic acid in a sample are provided. The method is a method for multiplex isothermal amplification-based sequencing and real-time analysis of multiple viral genomes. It can simultaneously detect SARS-CoV-2 and co-infecting respiratory viruses, and monitor mutations for up to 96 samples in real time. The method, termed NIRVANA for Nanopore sequencing of Isothermal Rapid Viral Amplification for Near real-time Analysis, showed high sensitivity and specificity for SARS-CoV-2 in 70 clinical samples. It also simultaneously detected other viral pathogens (e.g. influenza A) in clinical and municipal wastewater samples. It provides a rapid field-deployable solution of COVID-19 and co-infection detection and surveillance of the evolution of pandemic strains.

ASSAYS FOR SARS-COV-2 BY LESION INDUCED DNA AMPLIFICATION (LIDA)

Resumen de: US2024279753A1

Assays for SARS-CoV-2 are described, together with lesion induced DNA amplification (LIDA)-based methods for amplifying RNA or DNA.

Diagnostic Primers, Kits and Methods for Viral Detection

Resumen de: US2024279750A1

Provided is a primer set for detecting the N gene of SARS-COV-2 using a reverse transcription loop-mediated isothermal amplification (RT-LAMP) method, comprising at least a first F3 primer comprising a nucleotide sequence at least 90% identical to SEQ ID NO: 1, at least a first B3 primer comprising a nucleotide sequence at least 90% identical to SEQ ID NO: 2, at least a first F2 primer comprising a nucleotide sequence at least 90% identical to SEQ ID NO: 3, at least a first B2 primer comprising a nucleotide sequence at least 90% identical to SEQ ID NO: 4, at least a first F1c primer comprising a nucleotide sequence at least 90% identical to SEQ ID NO: 5 or to SEQ ID NO: 8, at least a first B1c primer comprising a nucleotide sequence at least 90% identical to SEQ ID NO: 6. Also provided are kits and methods for using the described primers, and a primer set for similarly detecting the S gene of SARS-COV-2.

MULTIPLEXED ANTIGEN-BASED DETECTION OF SARS-COV-2 AND OTHER DISEASES USING NANOMECHANICAL SENSORS

Resumen de: US2024277252A1

Nanomechanical sensors comprising an antibody-functionalized microcantilever and methods of using the same are described herein.

SMALL MOLECULE COMPOUNDS

Resumen de: US2024279172A1

The SARS-CoV-2 is highly contagious and has caused coronavirus disease 2019 (COVID-19) outbreaks worldwide. Some embodiments of the present invention relate to a method of ameliorating or treating a subject suffering from a SARS-CoV-2 infection. The method includes administering to the subject an antiviral composition comprising a therapeutically effective amount of a GC molecule or a pharmaceutically acceptable salt thereof.

CORE AMINO ACID SEQUENCE GROUP CAPABLE OF TARGET RECOGNIZING ANTI-NOVEL CORONAVIRUS NEUTRALIZING ANTIBODIES N-IGY-PABS AND USE THEREOF

Resumen de: US2024279286A1

Specifically disclosed are a core amino acid sequence group capable of target recognizing anti-novel coronavirus neutralizing antibodies N-IgY-pAbs and a use thereof. The core amino acid sequence group capable of target recognizing anti-novel coronavirus neutralizing antibodies N-IgY-pAbs includes 15 types of the amino acid sequences positioned in an S-ECD region and 5 types of the amino acid sequences positioned in a non-structural protein (NSP) region, and can be applied to a detection of the novel coronavirus, a design of therapeutic targets and a design of vaccine targets.

PLANT-BASED COMPOSITIONS AND METHODS FOR MODULATION OF INFLAMMATORY RESPONSE POST VIRAL INFECTION

Resumen de: WO2024173473A1

A polyphenol-rich composition is orally administered to alleviate a sign or symptom of a post-viral syndrome, and preferably post-COVID syndrome. Most typically, the composition comprises at least 50 wt% total catechins, at least 20 wt% total chlorogenic acids, and optionally up to 30 wt% total supplemental antioxidants. The composition may be formulated from a green coffee bean extract, a green tea extract, a turmeric extract, a tart cherry or extract thereof, a broccoli or extract thereof, and a kale or extract thereof. Notably, such compositions were effective in individuals post SARS-CoV2 infection to reduce proinflammatory cytokines and interleukins, increase NOHb, and to reduce reactive oxygen species due to mitochondrial dysfunction, iNOS activity, and NOX2 activity.

New medical use

Resumen de: GB2627263A

The compound sevuparin (a modified heparin) or a pharmaceutically acceptable salt thereof, for use in the treatment of endotoxemia. The treatment may be prophylactic. The endotoxemia may occur in conjunction with gram-negative or gram-positive bacteria, sepsis, septic shock, major surgical procedure(s) (e.g., thoracic (cardiac), abdominal, neurosurgical procedure), severe acute disease (e.g., pancreatitis, cholecystitis, intestinal arterial obstruction, portal vein thrombosis, aortic aneurysm rupture, aortic dissection), injury from major trauma, hepatic failure (non-cirrhotic or cirrhotic), hepatorenal syndrome, intestinal endotoxemia. The endotoxemia may be portal endotoxemia, or may be present in a subject having an autoimmune disease (e.g., inflammatory bowel disease (IBD), Crohn’s disease, ulcerative colitis), systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), or Covid-19. The use may be combination treatment with standard of care (SOC) therapy (e.g., low molecular weight heparin (LMWH)) for endotoxemia. Also claimed is the use of compound sevuparin or its pharmaceutically acceptable salt, for the manufacture of a medicament for the treatment of endotoxemia. Also claimed is a method of treatment of endotoxemia, comprising administering a therapeutically effective amount of sevuparin or its pharmaceutically acceptable salt, to a subject.

GENE CONSTRUCT FOR EXPRESSING MRNA

Resumen de: EP4417694A1

The present invention relates to a gene construct for expressing an mRNA, and a pharmaceutical composition, a vaccine composition, and a gene therapy composition, each comprising the gene construct. More specifically, the present invention relates to a gene construct including a coronavirus (SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2)-derived 5' untranslated region (UTR) and/or 3' untranslated region (UTR), and a pharmaceutical composition, a vaccine composition, and a gene therapy composition, each comprising the gene construct.

COVID-19 COVID-19 Vaccine

Resumen de: KR20240126800A

본 발명은 종래 이용되는 DNA 및 mRNA 백신보다 안정적이고, 최종 농도가 확보되며, SARS-CoV-2에 대한 T 세포 면역반응을 더 잘 일으킬 수 있는 COVID 19 예방용 펩타이드 기반 백신을 제공한다. 본 발명의 폴리펩타이드 백신은 SARS-CoV-2 스파이크 단백질의 구조 및 면역원성을 고려하여 고른 스파이크 단백질의 4개의 단편 중 적어도 하나를 포함한다.

ACE2-TARGETED COMPOSITIONS AND METHODS FOR TREATING COVID-19

Resumen de: AU2022367398A1

This invention provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2; and (iii) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide. This invention also provides related recombinant AAV vectors, recombinant AAV particles, compositions, prophylactic and therapeutic methods, and kits.

MODIFIED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS TARGETING SARS-COV-2

Resumen de: CA3235530A1

A self-assembled polypeptide complex comprises: (a) one or more fusion proteins comprising a nanocage monomer or subunit thereof linked to an Fc polypeptide, and (b) one or more fusion proteins comprising a nanocage monomer or subunit thereof linked to a SARS-CoV-2 binding moiety; wherein a plurality of the fusion proteins self-assemble to form a nanocage.

- NOBLE COLD-ADAPTED ATTENUATED MERS-CoV

Resumen de: WO2024167071A1

The present invention relates to a novel low-temperature-adaptive attenuated Middle East respiratory syndrome coronavirus (MERS-CoV) and uses thereof, in which, by stepwise adapting a MERS-CoV to low temperatures, a novel low-temperature-adaptive attenuated MERS-CoV that enables effective prevention of MERS-CoV infection was developed, and can be useful as a vaccine and therapeutic agent able to prevent Middle East respiratory syndrome.

CRISPR-CAS13 SYSTEM FOR DETECTING SARS-COV-2, AND KIT THEREOF AND METHOD THEREFOR

Resumen de: WO2024164381A1

Provided are a CRISPR-Cas 13 system for detecting SARS-CoV-2, and a kit thereof and a method therefor. The CRISPR-Cas13a system comprises Cas13a protein and crRNA or a complex formed by the Cas13a protein and the crRNA. The crRNA comprises a first guide RNA and a second guide RNA, and the first guide RNA and the second guide RNA are respectively selected from at least one of sequences SEQ ID NOs.1-33. The system, the kit and the method have the advantages of a simple scheme and high sensitivity, and can be accurately used for detecting SARS-CoV-2.

LIDOCAINE OR ARTICAINE FOR TREATING COVID-19, AUTOIMMUNE DISEASE OR CYTOKINE STORM RESPONSE

Resumen de: US2024269109A1

A composition including lidocaine or a salt thereof, or articaine or a salt thereof, is disclosed for use in the treatment of COVID-19 or an autoimmune disease or a condition in which an immune response caused by a disease or infection causes a cytokine storm. A pharmaceutical formulation including lidocaine, or a salt thereof, or articaine, or a salt thereof is disclosed. The pharmaceutical formulation is formulated to facilitate uptake by a lymphatic system with one or more suitable excipients.

NOVEL LOW-TEMPERATURE-ADAPTIVE ATTENUATED MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS

Resumen de: WO2024167071A1

The present invention relates to a novel low-temperature-adaptive attenuated Middle East respiratory syndrome coronavirus (MERS-CoV) and uses thereof, in which, by stepwise adapting a MERS-CoV to low temperatures, a novel low-temperature-adaptive attenuated MERS-CoV that enables effective prevention of MERS-CoV infection was developed, and can be useful as a vaccine and therapeutic agent able to prevent Middle East respiratory syndrome.

ANTIBODY MOLECULES BINDING TO SARS-COV-2

Resumen de: WO2024168061A2

Antibody molecules that specifically bind to a SARS-CoV-2 spike protein are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as COVID-19.

SARS-CoV-2 DETECTION METHOD AND KIT THEREFOR

Resumen de: WO2024166923A1

Disclosed are a high-performance anti-SARS-CoV-2 antibody, and a testing reagent using the anti-SARS-CoV-2 antibody. This SARS-CoV-2 detection method involves detecting SARS-CoV-2 in a sample by immunoassay using a monoclonal antibody or an antigen-binding fragment thereof that specifically reacts with an RNA-binding domain of an amino acid sequence of the SARS-CoV-2 N protein. This SARS-CoV-2 detection kit includes a monoclonal antibody or an antigen-binding fragment thereof that specifically reacts with an RNA-binding domain of the SARS-CoV-2 N protein.

SARS-CoV-2 DETECTION METHOD AND KIT THEREFOR

Resumen de: WO2024166921A1

Disclosed are a high-performance anti-SARS-CoV-2 antibody, and a testing reagent using the anti-SARS-CoV-2 antibody. This SARS-CoV-2 detection method includes detecting SARS-CoV-2 in a sample by immunoassay using a monoclonal antibody or an antigen-binding fragment thereof that specifically reacts with 301aa-319aa, 301aa-320aa or 351aa-375aa of the amino acid sequence of the SARS-CoV-2 N protein. This SARS-CoV-2 detection kit includes a monoclonal antibody or an antigen-binding fragment thereof that specifically reacts reacts with 301aa-319aa, 301aa-320aa or 351aa-375aa of the amino acid sequence of the SARS-CoV-2 N protein.

ANTI-SARS-COV-2 MONOCLONAL ANTIBODY AND IMMUNOASSAY METHOD AND IMMUNOASSAY INSTRUMENT FOR SARS-COV-2 USING SAME

Resumen de: WO2024166920A1

Disclosed are: a monoclonal antibody with which SARS-COV-2 contained in a test specimen can be rapidly, simply and highly sensitively detected and measured; and an immunoassay method and an immunoassay instrument for SARS-COV-2 using the monoclonal antibody. This monoclonal antibody or an antigen-binding fragment thereof includes heavy chains CDR1-CDR3 having specific amino acid sequences and light chains CDR1-CDR3 having specific amino acid sequences. This immunoassay method for SARS-COV-2 involves performing an immunoassay of SARS-COV-2 using an antigen-antibody reaction between the monoclonal antibody or an antigen-binding fragment thereof and SARS-COV-2 in a sample.

SARS-CoV-2 DETECTION METHOD AND KIT THEREFOR

Resumen de: WO2024166922A1

Disclosed are a high-performance anti-SARS-CoV-2 antibody, and a testing reagent using the anti-SARS-CoV-2 antibody. This SARS-CoV-2 detection method involves detecting SARS-CoV-2 in a sample by immunoassay using a monoclonal antibody or an antigen-binding fragment thereof that specifically reacts with the SARS-Cov-2 N protein. This SARS-CoV-2 detection kit includes a monoclonal antibody or an antigen-binding fragment thereof that specifically reacts with the SARS-Cov-2 N protein.

LIQUID PREPARATION CONTAINING NIRMATRELVIR AND RITONAVIR, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2024165081A1

Provided are a liquid preparation containing nirmatrelvir and ritonavir, and a preparation method therefor and the use thereof. Nirmatrelvir, ritonavir and other excipients are combined to prepare the liquid preparation, which has a high absorption rate, a high bioavailability and an accurate administration dosage and can be accurately administered at a reasonable dosage according to different symptoms. The phenomena that an existing Paxlovid tablet is inconvenient to administer due to the large dosage, has a low dissolution and poor bioavailability, and that multiple tablets need to be taken are solved, the patient medication adherence is improved, and the drug toxicity is reduced. The preparation process of the liquid preparation containing nirmatrelvir and ritonavir is simple, and large equipment is not needed. The liquid preparation containing nirmatrelvir and ritonavir retains the drug properties of nirmatrelvir and ritonavir, and can be used for preparing drugs for SARS-CoV-2.

METHODS OF ANALYZING SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2 (STNFR2) AND USES THEREOF

Resumen de: AU2023213693A1

The present disclosure relates to methods of testing immunomodulatory activity of cells, including, for example, mesenchymal stem cells and uses of said cells that are determined as having immunomodulatory activity for treating COVID-19 related acute respiratory distress syndrome (ARDS). Disclosed herein are in vitro methods of evaluating mesenchymal stem cells for their effective immunomodulatory effects in vivo.

ANTI-SARS-COV-2 ANTIBODIES DERIVED FROM CR3022

Resumen de: US2024270825A1

This disclosure provides antibodies and that can be administered to an individual that is infected with a virus. Antibodies herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies herein can be used to diagnose a SARS-CoV-2 infection.

ANTIBODIES THAT BIND SARS-COV-2 SPIKE PROTEIN

Resumen de: US2024270826A1

Described herein are antibodies that specifically recognize the SARS-CoV-2 spike (S) polypeptide, compositions comprising said antibodies, uses thereof, and methods employing said antibodies. Each antibody specifically recognizes the S1-RBD domain, S1-NTD domain, or S2 subunit of the SARS-CoV-2 spike polypeptide. Some antibodies are cross-reactive with variants of SARS-CoV-2 and other coronavirus spike polypeptides, such as SARS-CoV S, pangolin CoV S, bat SARS-like CoV S, and civet SARS-CoV S.

HUMAN NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 SPIKE S2 DOMAIN AND USES THEREOF

Resumen de: US2024270828A1

The disclosure is based, at least in part, on certain human monoclonal antibodies, or antigen binding fragments thereof, having unexpected broad neutralizing activities against SARS-CoV-2. The disclosed antibodies and/or antigen-binding fragments thereof are therapeutic agents for the treatment of SARS-CoV-2 infections and are suitable for use in therapeutic methods to protect individuals from SARS-CoV-2 infections.

Methods for treating SARS CoV-2 infections

Resumen de: AU2024205205A1

Provided are methods for treating 2019-nCoV virus (SARS-CoV-2) infections by administering nucleosides and prodrugs thereof, of Formula I: w3 Ri2 wherein the l' position of the nucleoside sugar is substituted.

FUSION PROTEINS COMPRISING SARS-COV-2 RECEPTOR BINDING DOMAIN

Resumen de: US2024270795A1

A fusion protein includes the SARS-COV-2 receptor binding domain (RBD) of the SARS-COV-2 spike protein or a fragment, and a N-terminal signal peptide, and at least one of the following: a polyhistidine tag, linker, an oligomerization tag, a region in spike protein outside RBD, a horseradish peroxidase binding domain or a protease cleavage site.

CORONAVIRUS NEUTRALIZING COMPOSITIONS AND ASSOCIATED METHODS

Resumen de: US2024270797A1

Provided are fusion proteins and modified proteins comprising a neutralizing polypeptide and an antibody (e.g., a non-neutralizing antibody) that specifically binds to an epitope in a conserved region of one or more coronavirus spike proteins. The fusion proteins and modified proteins are able to specifically bind to and neutralize a broad spectrum of coronaviruses, including SARS-CoV-2 and all known SARS-COV-2 variants of concern (e.g., the Delta and Omicron variants). Also provided are various compositions of such proteins, methods of their use, nucleic acids encoding such proteins or domains thereof, constructs, expression cassettes, and vectors containing such nucleic acids, and host cells capable of expressing these proteins or domains thereof. Additionally provided are prophylactic and therapeutic methods employing the fusion proteins and/or modified proteins of the disclosure.

SESQUITERPENOID DERIVATIVE AND USE THEREOF IN PREPARING BROAD-SPECTRUM ANTIVIRAL DRUG

Resumen de: US2024270754A1

A sesquiterpenoid derivative and use thereof in preparing a broad-spectrum antiviral drug provided. The sesquiterpenoid derivative can stimulate heterogeneous nuclear ribonucleoprotein A2/B1, activate the cell signal pathway of TANK-binding kinase 1-interferon regulatory factor 3, and increase the expression and secretion of endogenous type I interferon. As a result, it can inhibiting various viruses and can be used as a broad-spectrum antiviral drug for preventing or treating various viral infectious diseases and symptoms, including Covid-19, vesicular stomatitis virus VSV-G, AIDS virus, hepatitis C virus, Japanese encephalitis virus, influenza virus, poliovirus, Coxsackie virus, dengue virus, rotavirus, tobacco mosaic virus, measles virus, mumps virus, Ebola virus, Marburg virus, herpes virus and adenovirus. Sesquiterpenoid derivatives can be made as a raw material into oral dosage form such as tablet, capsule and dripping pill, or clinically acceptable pharmaceutical preparation such as inhalant and injection.

Airborne monitor to detect SARS-CoV-2 wild-type and mutations in airborne samples using Nucleic Acid Amplification Techniques (NAT)

Resumen de: US2024269671A1

The disclosure provides example devices and methods for virus and bacterium detection and identification. The example device includes (a) a housing having an air inlet and an air outlet, (b) a substrate disposed within the housing, where the at least one substrate has a through-slot, where the substrate has a plurality of wells, (c) an air-handling and precipitation chamber, a reagent and reaction chamber, and a detection chamber arranged in series and each coupled to the top surface of the substrate, (d) a first actuator coupled to the substrate and configured to rotate the substrate, (e) a second actuator coupled to and configured to rotate the air-handling and precipitation chamber, the reagent and reaction chamber, and the detection chamber, and (f) at least one processor electrically coupled to the air-handling and precipitation chamber, the reagent and reaction chamber, the detection chamber, the first actuator, and the second actuator.

COVID-19 VACCINES WITH TOCOPHEROL-CONTAINING SQUALENE EMULSION ADJUVANTS

Resumen de: US2024269270A1

Provided are novel vaccines for prophylactic treatment of SARS-COV-2 infections and COVID-19 and methods of making the vaccines, wherein the vaccines contain an oil-in-water emulsion comprising tocopherol and squalene.

TEMPERATURE-CONTROLLABLE, SELF-REPLICATING RNA VACCINES FOR VIRAL DISEASES

Resumen de: US2024269268A1

The present disclosure relates to mRNA, self-replicating RNA, and temperature-sensitive, self-replicating RNA encoding a coronavirus nucleocapsid protein or an influenza virus nucleocapsid protein in operable combination with a mammalian signal peptide. The present disclosure relates to mRNA, self-replicating RNA, and temperature-sensitive, self-replicating RNA encoding other viral nucleocapsid protein(s) in operable combination with a mammalian signal peptide. The RNA constructs are suitable for active immunization against a virus in a mammalian subject, such as a human subject.

BROAD-SPECTRUM MULTI-ANTIGEN PAN-CORONAVIRUS VACCINE

Resumen de: US2024269266A1

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

HUMAN CORONAVIRUS 229E DERIVED PEPTIDES

Resumen de: US2024269264A1

The invention relates to common cold coronavirus peptides derived from HcoV-229E, and related polynucleotides, complexes pharmaceutical compositions, methods of treatment, and medical uses.

METHODS, KITS, AND APPROACHES FOR VIRAL VACCINES

Resumen de: US2024269262A1

The invention provides methods of making vaccines against viruses, including against SARS-Cov-2. Such methods entail identifying areas of a viral genome that are highly conserved and making vaccines that target the highly conserved areas. The invention provides a polypeptide vaccine comprising a SARS-Cov-2 polypeptide or an immunogenic fragment thereof and a pharmaceutically acceptable excipient. The invention provides a polynucleotide vaccine comprising a polynucleotide encoding a SARS-Cov-2 polypeptide or immunogenic fragment thereof linked to a heterologous promoter and a pharmaceutically acceptable excipient. The invention provides methods for effecting prophylaxis of or treating SARS-Cov-2 infection comprising a step of administering a polypeptide vaccine and/or a polynucleotide vaccine to a subject in need thereof.

EXPRESSION OF SARS-COV PROTEINS, NUCLEIC ACID CONSTRUCTS, VIRUS LIKE PROTEINS (VLPS) AND METHODS RELEVANT THERETO

Resumen de: US2024269261A1

The present invention relates to expression of SARS-CoV like virus proteins S, M and E proteins; recombinant polynucleotides, polypeptides; constructs, virus-like particles (VLPs); immunogenic compositions or vaccines comprising Virus Like Particles (VLPs). Method of producing the VLPs/expressing the multi-subunit virus like proteins and method for co-expression of multi-subunit and virus like proteins (VLPs) are also provided. The present invention also provides strategies, methods, systems, kits and combinations for scalable expression, purification and enhanced production of the virus like proteins of SARS-CoV while maintaining their size range and composition. Such multi-subunit VLPs can be utilized to make immunogenic compositions or vaccines.

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING LUNG DISEASE

Resumen de: US2024269242A1

Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are SP-A peptides and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD). The compositions may comprise peptides having an amino acid sequence of Ac-WGKEQCVE(Nle)(Pego3)-Hdc (SEQ ID NO: 24) The peptide compositions may also be used to treat COVID-19.

METHODS RELATED TO AN ALTERNATIVE CONFORMATION OF THE SARS-COV-2 SPIKE PROTEIN

Resumen de: US2024274239A1

Described are methods related to a newly discovered alternative conformation of the SARS COV 2 Spike protein.

MODIFIED PIV5 VACCINE VECTORS: METHODS OF MAKING AND USES

Resumen de: WO2024167866A2

A CVB viral expression vector comprising a PIV5 W3A viral genome that contains mutations at amino acid residue S157 or S156 in the P/V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) to phenylalanine (F) or asparagine (N) and wherein the SH gene has a deletion of the SH open reading frame or a deletion of an entire SH gene transcript unit. The CVB viral expression vector wherein the vector expresses a heterologous polypeptide comprising a SARS-CoV-2 spike (S), and/or nucleocapsid (N) and/or membrane (M) proteins, RSV fusion protein (F) or other antigens.

METHOD FOR OPTIMIZING VIRUS MEMBRANE FUSION INHIBITOR, BROAD-SPECTRUM ANTI-CORONAVIRUS LIPOPEPTIDE AND USE THEREOF

Resumen de: EP4414377A1

The present disclosure relates to a method for optimizing a virus membrane fusion inhibitor, a broad-spectrum anti-coronavirus lipopeptide and use thereof. The present disclosure provides compounds or pharmaceutically acceptable salts thereof or derivatives thereof, wherein the compounds are shown in formula (I) or formula (II), X₁ is an amino-terminal protecting group; X₂ is a polypeptide with an amino acid sequence of (EAAAK)n or A(EAAAK)nA; X₃ is lysine or cysteine or 2,3-diaminopropionic acid or ornithine or 2,4-diaminobutyric acid or 2,7-diaminoheptonic acid; X₄ is a lipophilic compound group modified on X₃ or X₄ is a lipophilic compound group modified on K in X₂; X₅ is a carboxyl-terminal protecting group. The compounds of the present disclosure have a stable property, are highly efficient and broad-spectrum novel coronavirus membrane fusion inhibitors, and used in preparation of pharmaceutical compositions for preventing and treating a disease caused by a coronavirus. The pharmaceutical compositions are used for preventing and treating the diseases caused by the coronavirus.

ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF I

Resumen de: AU2022361501A1

The present disclosure relates to proteins which bind to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof.

ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF II

Resumen de: AU2022358743A1

The present disclosure relates to anti-SARS-COV-2 antibodies and uses thereof in detecting intact multimeric and/or intact trimeric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a sample.

ANTIBODIES TO CORONAVIRUS SARS-COV-2

Resumen de: WO2023070051A1

Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.

NOVEL UNIVERSAL ANTI-RNA VIRUS AGENTS

Resumen de: US2024262857A1

Deuterated and/or methylated N4-hydroxycytidine (NHC) analogs, with deuteration at one or both of the 2′- and 3′-positions on the ribo-sugar moiety and/or methylation of the 3′-positions on the ribo-sugar moiety, pharmaceutical compositions comprising one or more of these compounds, and, optionally, at least one additional therapeutic agent, and methods of treating or preventing infections caused by RNA viruses, curing an infection by an RNA virus, or reducing the biological activity of an RNA virus, are disclosed. Representative RNA viruses include, but are not limited to, Coronaviridae, such as MERSr-CoV, SARS-CoV-1, SARSCoV-2, HCoV-OC43, HCoV-229E, HCoV-NL63, and HCoV-HKU1, Picornaviridae, Hepeviridae, Noroviruses, Zika, Dengue, Mayaro, Influenza A and B, Parainfluenza, HCV, Rinovirus, tick-borne viruses, Ebola, Lassa, RSV, adenoviruses, enteroviruses, metapneumoviruses, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), and Chikungunya fever (CHIK).

POLYPEPTIDE FRAGMENTS, IMMUNOGENIC COMPOSITION AGAINST SARS-CoV-2, AND IMPLEMENTATIONS THEREOF

Resumen de: US2024262869A1

The present disclosure discloses the polypeptide fragment having an amino acid sequence with at least 95% identity to the amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 6. The present disclosure also discloses nucleic acid fragment encoding the polypeptide fragment as described herein. Moreover, the present disclosure also discloses recombinant construct, recombinant vector and recombinant host cells. Also disclosed herein is an immunogenic composition comprising the polypeptide fragment as described herein, and a method for preparing the said immunogenic composition. The immunogenic composition is in form of vaccine. The polypeptide fragment and/or immunogenic composition is capable of eliciting protection against severe acute respiratory syndrome coronavirus 2. A kit comprising the polypeptide, or the immunogenic composition as described herein is also disclosed.

NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2

Resumen de: US2024262892A1

Provided are novel neutralizing antibodies against spike protein of SARS-COV-2, and the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.

RESPIRATORY BIOMARKER PANEL

Resumen de: WO2024163366A2

The present disclosure provides a set of primers and optional probes for identifying the presence of α-coronavirus, β-coronavirus, SARS-CoV-2, adenovirus, Chlamydia pneumoniae, Influenza A, Influenza B, metapneumovirus, rhinovirus/enterovirus, mycoplasma, Bordetella spp., parainfluenza, and respiratory syncytial virus (RSV), which can be included with (e.g., in at kit) or in a cartridge for automated detection of these pathogens by nucleic acid amplification. This disclosure also provides related detection methods, as well as cartridges, systems, and kits useful in such methods.

PEDIATRIC SARS-COV-2 ANTIBODIES AND USES THEREOF

Resumen de: WO2024163949A2

The present disclosure relates to antibodies and uses thereof for treating, preventing, and detecting coronavirus infection.

Optimized RNAi Agents for Inhibiting Expression of Coronavirus (CoV) Viral Genomes, Compositions Thereof, and Methods of Use

Resumen de: WO2024163750A2

Described are optimized RNAi agents, compositions that include RNAi agents, and methods for inhibition of coronavirus (CoV) viral genome. The optimized CoV RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a SARS-CoV-2 viral genome, and the targeted portions of the genome are conserved across a variety of known coronaviruses. Pharmaceutical compositions that include one or more optimized CoV RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described CoV RNAi agents to pulmonary cells, in vivo, provides for inhibition of CoV viral genome expression, including SARS-CoV-2, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including COVID-19.

POLYCLONAL ANTIBODIES TO TREAT SARS-COV-2

Resumen de: WO2024163734A1

A composition, method of treating COVID-19, and use of the composition for administration to treat COVID-19 are provided. The composition includes polyclonal antibodies derived from human milk. The human milk is pooled and selected from human milk with polyclonal antibodies that includes an intact antibody that recognize SARS-CoV-2 viral particles

APTAMER BASED DETECTION OF SARS-COV-2 INFECTION

Resumen de: WO2024161418A1

The present invention relates to development of novel ssDNA aptamers comprising the oligonucleotide sequence that detect receptor-binding domain (RBD) of Severe Acute Respiratory Syndrome Corona virus (SARS-nCoV-2) infection. The ssDNA aptamers of the present invention may be used in lateral flow assays, electrochemical sensors and calorimetric sensors using gold nanoparticles. The present invention also relates to an analytical composition comprising said ssDNA aptamers. Further, the present invention also relates to a diagnostic kit for detecting RBD of SARS-nCoV-2.

CAMELID-DERIVED NANOBODY TARGETING SHARED EPITOPE OF SARS-COV-2 RBD AND RECEPTOR ACE2 THEREOF

Resumen de: WO2024159694A1

A camelid-derived nanobody targeting a shared epitope of SARS-CoV-2 RBD and receptor ACE2 thereof. The nanobody or an antigen binding fragment thereof simultaneously binds to key sites F486, Q493 and S494 of SARS-CoV-2 RBD. The nanobody VHH5-05 obtained by means of screening and purification not only exhibits a strong binding ability to a phage displaying the wild-type SARS-CoV-2 RBD, but also exhibits a certain binding ability to a phage displaying the Beta mutant strain RBD and the Delta mutant strain RBD.

CRISPR-Cas13 System, Kit and Method for Detecting SARS-CoV-2

Resumen de: US2024263256A1

Provided herein is a CRISPR-Cas13 system, a kit and a method for detecting SARS-COV-2. The CRISPR-Cas13a system includes a Cas13a protein and crRNA, or a complex formed by Cas13a protein and crRNA. The crRNA includes a first guide RNA and a second guide RNA, the first guide RNA and the second guide RNA having at least one sequence selected from SEQ ID NOs: 1 to 33, respectively.

BOOSTING SARS-COV-2 IMMUNITY WITH A LENTIVIRAL-BASED NASAL VACCINE

Resumen de: AU2023207825A1

The invention relates to the field of immunity against coronaviruses. In this respect, the invention provides a lentiviral-based immunogenic agent that is suitable for use in boost or target immunization treatment in a subject, in particular a human subject, who had previously developed an immunity against Severe Acute Respiratory Syndrome coronavirus 2 (SARS- CoV-2) based on: (i) vaccination with the first generation of vaccines against SARS-CoV-2 infection or disease such as a protein, an mRNA, an adenovirus, an inactivated virus or a protein subunit vaccine composition against SARS-CoV-2 infection or disease, in particular a protein- or an mRNA-based vaccine, or (ii) SARS-CoV-2-induced or correlated disease. The invention accordingly concerns a lentiviral-based immunogenic agent that in particular may help overcome the deficiencies of available vaccines against SARS-CoV-2, especially may be efficient in overcoming the waning immune response or insufficient cellular memory response observed after immunization with available first generation of vaccines such as a protein, an mRNA, an adenovirus, an inactivated virus or a protein subunit vaccine, in particular protein or mRNA vaccine, by triggering a mucosal humoral and cellular immune response against coronaviruses, including a long-lasting immune response.

METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS

Resumen de: AU2023209914A1

Compositions and methods related to the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) including viral pneumonia (such as COVID-19 pneumonia) wherein the subject has a PaO

PSEUDOTYPED LENTIVIRAL VECTORS

Resumen de: AU2022422579A1

The present invention relates to pseudotyped lentiviral vectors, particularly to pseudotyped with a modified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, as well as related constructs, methods and therapeutic indications.

VACCINE COMPOSITIONS AND THEIR USE

Resumen de: AU2022418989A1

The invention relates to immunogenic compositions and their use as a vaccine for the prevention of coronavirus disease in a human subject. More specifically, the invention relates to methods of use of an immunogenic composition in the prevention of coronavirus disease in a human subject in need thereof, said immunogenic composition comprising: a fusion protein comprising (i) a SARS-Cov2 nucleocapsid N antigen and, (ii) a carrier protein comprising a self-assembling polypeptide derived from C4bp oligomerization domain and a positively charged tail.

TLR7 AGONIST CONJUGATED PEPTIDE-BASED NOVEL CORONAVIRUS NANOEMULSION VACCINE AND PREPARATION THEREOF

Resumen de: US2024261391A1

The present invention relates to a novel coronavirus vaccine using a TLR7 agonist conjugated peptide as an antigen and an emulsion as an adjuvant. An antigen polypeptide of the conjugated peptide is a polypeptide derived from an S protein of SARS-COV-2, and the adjuvant is an oil-in-water nanoemulsion containing squalene. The conjugated peptide nanoemulsion vaccine preparation of the present invention is thermally stable, and can induce a high level of protective humoral immune response in a cynomolgus monkey, and the neutralizing antibody titer of antiserum after immunization of cynomolgus monkey is high, such that invasion of wild-type strain and mutant novel coronavirus can be blocked. The vaccine of the present invention has a nearly complete protection effect on the upper and lower respiratory tracts of the cynomolgus monkey in a cynomolgus monkey SARS-COV-2 challenge test. The nanoemulsion vaccine of the present invention is fast and convenient to prepare, and can realize large-scale production in a short term for coping with the novel coronavirus outbreak.

NITRIC OXIDE DONORS, COMPOSITIONS, AND METHODS OF USE

Resumen de: US2024261243A1

Disclosed are compositions comprising NO donors formulated for effectively treating disease states, such as microbial infections, including Covid-19 infections. Mucoadhesive agents, chelating agents, and gallium enable highly efficacious formulations for treating infections, particularly when the nature of the pathogenic species is unknown.

SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE

Resumen de: US2024261393A1

The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Methods of using the compositions as a COVID-19 vaccine for the treatment of a coronavirus infection are also provided.

COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES AGAINST CLASS I FUSION PROTEIN VIRUSES

Resumen de: US2024261394A1

Provided are modified bacteria and derivatives thereof that express nucleotide sequence encoding an antigen of a viral family selected from the group comprising Retroviridae (e.g., HIV, including a HIV Fusion Peptide antigen), Orthomyxoviridae, Paramyxoviridae, Arenaviridae, 5 Filoviridae, and/or Coronaviridae (e.g., an SARS-CoV, SARS-CoV-2 Fusion Peptide, and/or PEDV). In some embodiments, the bacterium has a reduced genome and induces an enhanced immune response against the viral antigen of interest when administered to a subject. In some embodiments, the viral (e.g., SARS-CoV, 10 SARS-CoV-2, PEDV, and/or HIV) antigen is expressed on a surface of a bacterium. Also provided are method for producing antibodies against viral antigens, vaccine compositions, methods for vaccinating subjects, methods for treating viral infections in subjects, and expression vectors for expressing viral antigens including but not limited to coronavirus (e.g., SARS-CoV, SARS-CoV-2, and/or PEDV) antigens and/or HIV antigens on the surface of reduced 15 genome bacteria.

INHIBITORS OF SARS-COV-2 VIRAL REPLICATION AND USES THEREOF

Resumen de: US2024261307A1

This invention is in the field of medicinal pharmacology. In particular, the present invention relates to pharmaceutical agents which function as inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral replication and/or SARS-CoV-2 related viral 3CL protease (Mpro) activity, which function as therapeutics for the treatment of conditions caused by the SARS-CoV-2 virus (e.g., COVID-19), and which function as therapeutics for the treatment conditions related to SARS-CoV-2 related Mpro activity.

HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19

Resumen de: US2024261316A1

The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.

A DEVICE FOR DETECTING HEALTH DISORDERS FROM BIOLOGICAL SAMPLES AND A DETECTION PROCESS

Resumen de: US2024264146A1

The present invention relates to instruments and processes for detecting compounds in gas samples. In particular, for detecting health disorders from biological samples, more preferably for detecting diseases from breath samples of a mammal. It is included among the methods and instruments for the diagnosis of COVID-19.

DEVELOPMENT AND VALIDATION OF A 2-GENE HOST-VIRAL TRANSCRIPTOMIC CLASSIFIER FOR ENHANCED COVID-19 DIAGNOSIS

Resumen de: US2024263254A1

Provided herein are lists of combined host-viral gene markers that can be used for identifying COVID-19 in a subject and/or determining severity of disease. The host-viral diagnostic methods, compositions and systems disclosed herein are used to classify human subjects pre-diagnosis, with or without symptoms of COVID-19, based on the expression levels of the identified gene markers.

METHOD FOR PREDICTING DEVELOPMENT OF SEVERE SYMPTOM OF COVID-19 USING EXOSOMAL PROTEIN MARKER IN BLOOD

Resumen de: US2024263234A1

The present invention provides a method for predicting the development of a severe symptom in a COVID-19 patient using a level of RNA of COPB2, KRAS, PRKCB, RHOC, CD147, CAPN2, ECM1, FGG, MFAP4, ADI1, AK1, MGAT1, CLDN3, CRP, UQCRC2, FGA, FGB, FGL1, GPX1, GSK3B, LBP, PDGFC, RAB13, RAP1B, SLC6A4, UBA7, or the like contained in the blood of a patient.

BINDING POLYPEPTIDES AGAINST SARS COV-2 AND USES THEREOF

Resumen de: US2024262893A1

Provided herein are binding polypeptides, such as binding peptides and antibodies, against a SARS CoV-2. The binding polypeptides relate to or are based on bovine antibodies, particularly those containing an ultralong CDR3. Also provided herein are methods of treating a virus infection, such as a coronavirus infection, by delivering to a subject in need a provided binding polypeptide.

PROCYANIDINS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION TRIGGERED BY COVID-19

Resumen de: ZA202213765B

The invention relates to a natural composition for medical purposes and more specifically to a composition comprising procyanidins, for use in the prevention or treatment of endothelial inflammation and/or endothelial systemic dysfunction triggered by Corona virus disease 2019 (COVID-19) including symptomatic post-COVID-19 subjects recovering from COVID-19.

COVID-19 A Machine Learning Model Learning Method Machine Learning-based COVID-19 Symptom Detection Method and Computer-readable Recording Medium on Which A Program Is Recorded

Resumen de: KR20240120370A

본 발명은 기계학습 모델 학습 방법, 기계학습 기반 COVID-19 전조증상 감지 방법 및 이를 수행하는 프로그램이 기록된 컴퓨터 판독이 가능한 기록매체에 관한 것으로, 보다 구체적으로, 적어도 하나의 프로세서에 의하여, 다수의 COVID-19 감염자가 각각 착용하고 있는 웨어러블 디바이스에 기록된 데이터가 학습 데이터로 획득되는 학습 데이터 획득단계, 상기 적어도 하나의 프로세서에 의하여, 상기 학습 데이터를 필터링한 후 이동평균(Moving Average; MA)이 이용되어 데이터 추세가 분석되는 학습 데이터 전처리 단계 및 상기 적어도 하나의 프로세서에 의하여, 전처리된 학습 데이터가 이용되어 지지 벡터 기반의 이상 탐지 기법으로 학습되고, COVID-19 감염증상여부를 출력하는 기계학습 모델이 생성되는 모델 학습 단계를 포함하는 기계학습 모델 학습 방법, 기계학습 기반 COVID-19 전조증상 감지 방법 및 이를 수행하는 프로그램이 기록된 컴퓨터 판독이 가능한 기록매체에 관한 것이다.

RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING SPIKE PROTEIN OF SARS-COV-2 DELTA VARIANT AND USES THEREOF

Resumen de: WO2023056351A2

Described herein are recombinant Newcastle disease viruses ("NDVs") comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotide sequence encoding a protein comprising a SARS-CoV-2 delta variant spike protein or portion thereof. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 delta variant spike protein ectodomain and NOV F protein transmembrane and cytoplasmic domains. The recombinant NDVs and compositions thereof are useful for the immunizing against SARS- CoV-2 delta variant as well as the prevention of COVID-19.

COMPOSITIONS, KITS, AND METHODS FOR DUPLEX IMMUNOASSAY FOR ANTI-SARS-COV-2 ANTIBODIES

Resumen de: CN118043347A

Kits containing a multiplex chemiluminescent detection system and microfluidic devices and methods for detecting the presence and/or concentration of anti-SARS-CoV-2 antibodies in a sample are disclosed. Kits, microfluidic devices, and methods utilize singlet oxygen activatable chemiluminescent compounds in combination with two or more fluorescent molecules that emit light at different wavelengths. In certain non-limiting embodiments, the kits, microfluidic devices, and methods can differentiate an anti-SARS-CoV-2 antibody generated in response to vaccination from an anti-SARS-CoV-2 antibody generated in response to infection.

RECOMBINANT FUSION PROTEIN DERIVED FROM HR REGION OF S2 PROTEIN OF SARS-COV-2 AND APPLICATION OF RECOMBINANT FUSION PROTEIN

Resumen de: EP4410843A1

Disclosed are a recombinant fusion protein derived from an HR region of an S2 protein of SARS-CoV-2 and an application of the recombinant fusion protein. The SARS-CoV-2 recombinant fusion protein is a recombinant fusion protein obtained by linking two membrane fusion-related conserved amino acid sequences HR1 and HR2 of the SARS-CoV-2 membrane protein S2 protein by means of a linking peptide. The recombinant fusion protein can be induced and expressed in Escherichia coli, has high expression quantity, and is easy to purify. The SARS-CoV-2 recombinant fusion protein provided by the present invention can form and maintain a stable dimer structure, simulates the conformation of a SARS-CoV-2 membrane fusion intermediate state, can be used as a detection raw material for detecting a SARS-CoV-2 membrane fusion process, has good anti-SARS-CoV-2 activity and good immunogenicity, and has a wide application prospect in the fields of development of drugs for preventing or treating SARS-CoV-2 proteins and development of SARS-CoV-2 vaccines and anti-SARS-CoV-2 antibodies.

POLYMERS OBTAINED BY THE REACTION OF A PHENOLIC COMPOUND AND A CARBONYL COMPOUND AS ANTI-SARS-COV-2 AGENTS

Resumen de: WO2023052517A1

The present invention relates to a condensation product, obtained or obtainable by the reaction of phenol, formaldehyde, sulfuric acid and urea, or a pharmaceutical composition comprising the same for use in a method for the prevention or treatment of Coronavirus disease 2019 (COVID-19) and/or for the prevention or treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to a pharmaceutical set comprising such a pharmaceutical composition for the same use and to such a pharmaceutical composition or pharmaceutical set.

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VIRAL INFECTIOUS DISEASES, CONTAINING EFAVIRENZ AND FLUOXETINE AS ACTIVE INGREDIENTS

Resumen de: EP4410293A1

The present invention relates to a pharmaceutical composition for preventing or treating viral infectious diseases, containing efavirenz and fluoxetine as active ingredients. It has been identified that when a complex, mixture or combination of efavirenz and fluoxetine is administered or a complex, mixture or combination of efavirenz and fluoxetine, to which a biguanide-based compound metformin is added, is administered, antiviral efficacy against various zoonotic viruses including SARS-CoV-2 is remarkably higher than when each is administered alone, and thus efavirenz and fluoxetine, in addition to the biguanide-based compound, can be effectively used as active ingredients of a composition for preventing or treating viral infectious diseases.

ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF

Resumen de: US2024228591A1

The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-COV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.

2 SARS-CoV-2 specific aptamer and use thereof

Resumen de: KR20240118210A

본 발명은 사스 코로나 바이러스 2(SARS coronaviru 2; SARS-CoV-2) 특이적 압타머 및 이의 용도에 관한 것이다. 보다 구체적으로 본 발명에서 제공하는 압타머는 사스 코로나 바이러스 2 스파이크 단백질, 특히 사스 코로나 바이러스 2 스파이크 단백질의 서브유닛 1에 높은 결합력으로 특이적 결합하므로 이를 이용하여 검출용 조성물, 키트 등에 유용하게 이용할 수 있다.

PROCYANIDINS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION TRIGGERED BY COVID-19

Resumen de: ZA202213765B

The invention relates to a natural composition for medical purposes and more specifically to a composition comprising procyanidins, for use in the prevention or treatment of endothelial inflammation and/or endothelial systemic dysfunction triggered by Corona virus disease 2019 (COVID-19) including symptomatic post-COVID-19 subjects recovering from COVID-19.

ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS, AND METHODS

Resumen de: WO2024159117A1

Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.

SULFONAMIDE-1H-PYRROLE-2-CARBOXAMIDE INHIBITORS OF SARS-COV-2 NSP14 METHYLTRANSFERASE AND DERIVATIVES THEREOF

Resumen de: WO2024158863A1

Methods and compositions for treating SARS-CoV-2 and COVID-19 are disclosed. Sulfonamide-1H-pyrrole-2-carboxamides of the following formula inhibit the SARS-CoV-2 methyltransferase enzyme NSP14 and are therefore useful for treating SARS-CoV-2 and COVID-19.

1,3-INDOLE-PROPANAMIDE INHIBITORS OF SARS-COV-2 PLPRO/NSP3 AND DERIVATIVES THEREOF

Resumen de: WO2024158872A1

Methods and compositions for treating SARS-CoV-2 and COVID-19 are disclosed. 1,3-indole propanamides of the following formula (I) inhibit the SARS-CoV-2 PLpro/NSP3 protein and are therefore useful for treating SARS-CoV-2 and COVID-19.

SULFONE-1H-PYRROLE-2-CARBOXAMIDE INHIBITORS OF SARS-COV-2 NSP14 METHYLTRANSFERASE AND DERIVATIVES THEREOF

Resumen de: WO2024158875A1

Methods and compositions for treating SARS-CoV-2 and COVID-19 are disclosed. Sulfone-1H-pyrrole-2-carboxamides of the following formula inhibit the SARS-CoV-2 PLpro/NSP3 protein and are therefore useful for treating SARS-CoV-2 and COVID-19.

COMPOSITIONS AND METHODS USING TETRAHYDROCANNABINOL AND COMPOSITIONS INCLUDING SAME FOR TREATING INDICATIONS INVOLVING INFLAMMATION

Resumen de: WO2024159198A2

Compositions and methods for treating any one of the disclosed indications involving inflammation in a subject in need thereof, which includes administering to the subject a therapeutically effective amount of a composition including a tetrahydrocannabinol (THC) constituent. The composition is beneficial in reducing inflammation and/or inhibiting the production of pro-inflammatory cytokines and/or converting inflammatory M1 phenotype macrophages into anti-inflammatory M2 phenotype macrophages. It is useful in treating indications such as COVID-19, PASC/long COVID, effects related to ROSC, exposure to chemical or biological weapons, chemotherapy side effects, graft versus host disease, kidney damage from inflammation, chronic obstructive pulmonary disease, aging, and ARDS resulting from COVID-19, mechanical ventilation, shock, sepsis. In further embodiments, the composition may further include fluvoxamine, melatonin, or other disclosed constituents.

SARS-COV-2 VACCINE CONSTRUCTS

Resumen de: WO2024158722A1

The present disclosure describes, inter alia, fusion polypeptides comprising a SARS-CoV-2 Spike polypeptide fragment comprising at least a portion of the N-terminal domain, domains CD1, RBM, and CD2, and at least a portion of CTD1, wherein the N- or C-terminus of the Spike polypeptide fragment is fused to a heterologous N- or C-terminal tag comprising at least two, at least three, or at least four amino acids, as well as polynucleotides and vectors expressing such fusion polypeptides, pharmaceutical compositions comprising the polypeptides or polynucleotides encoding them, host cells for their production, and methods of using such pharmaceutical compositions as vaccines or for generation of antibodies.

Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19

Resumen de: AU2022420026A1

Infectious diseases remain a problem throughout the world. The outbreak of sudden acute respiratory syndrome coronavirus 2 (SARS-Co V-2) has infected more than 640 million people worldwide. SARS-Co V-2 causes the disease COVID-19. Mutations in the SARS-CoV-2 S spike protein enable SARS-CoV-2 variants to escape neutralizing monoclonal antibodies produced from previous infection with SARS-CoV2 or by vaccination. The present invention provides antibodies that bind to the SARS-Co V-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.

MINERALOCORTICOID RECEPTOR ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF A CORONAVIRUS INFECTION

Resumen de: US2024252517A1

The present invention relates to a novel therapy for preventing viral spread and/or reducing viral load in a patient and, in particular, a novel therapy for preventing viral spread and/or reducing viral load in a patient suffering with COVID-19. The therapy involves the administration of a mineralocorticoid receptor antagonist such as, for example, spironolactone.

ANTIVIRAL PHARMACEUTICAL COMPOSITION

Resumen de: US2024252529A1

Sulphated polysaccharides for use as an antiviral active ingredient in an antiviral effective amount in a pharmaceutical composition or medicament for the prophylactic or therapeutic intervention of a SARS-CoV-2 infection in a human individual or non-human animal.

ACE2 FUSION PROTEINS AND USES THEREOF

Resumen de: US2024252601A1

The present disclosure provides ACE2 fusion proteins, comprising multimerization moieties linked to ACE2 moieties, that specifically bind to RBD regions of SARS-CoV and/or SARS-CoV-2. The present disclosure further relates to the methods of producing the ACE2 fusion proteins, pharmaceutical compositions comprising of the ACE2 fusion proteins, and methods of use of the ACE2 fusion proteins to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.

LIVE-ATTENUATED VIRUS VACCINE

Resumen de: US2024252616A1

This invention relates to a codon deoptimized severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) genome. In particular, embodiments of the invention concern a vaccine comprising live attenuated SARS-COV-2 comprising a partly codon deoptimized viral genome, SARS-COV-2 comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. The ORF1a region of the viral genome has been codon deoptimized.

Coronavirus Constructs and Vaccines

Resumen de: US2024252619A1

Disclosed herein are nucleic acid constructs comprising a replication defective Zika virus vector and one or more coronavirus sequences and compositions thereof. The constructs relates to compositions and methods for inducing an immune response against coronavirus antigens due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) outbreak. The results herein indicate that these coronavirus constructs are safe and will induce an immune response that may provide protection against coronaviruses.

NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS

Resumen de: US2024252622A1

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

VIRUS-LIKE PARTICLE VACCINE FOR CORONAVIRUS

Resumen de: US2024252621A1

The present disclosure relates to targeting SARS-CoV-2, in particular, prevalent strains of SARS-CoV-2, and methods of using such vaccines to induce neutralizing antibody levels against SARS-CoV-2.

COMPOSITIONS AND METHODS FOR INHIBITING AN INFLAMMATORY RESPONSE AND TREATING INFLAMMATORY DISEASES

Resumen de: US2024254166A1

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for inhibiting the ability of neutrophils, or polymorphonuclear leukocytes (PMNs), to release reactive oxygen species (ROS), thus also inhibiting or ameliorating neutrophil (PMN) contribution to an inflammatory response, thus also treating, ameliorating or preventing neutrophil (PMN)-meditated inflammatory-related pathologies such as acute respiratory distress syndrome (ARDS), including ARDS caused by a viral infection such as COVID-19.

GENETICALLY MODIFIED CLOSTRIDIUM STRAINS EXPRESSING RECOMBINANT ANTIGENS AND USES THEREOF

Resumen de: US2024254167A1

The present invention relates to genetically modified Clostridium strains that provide improved combinations of functional features useful for several medical applications requiring the preparation and administration of antigens. In particular, clinical grade spores generated from the Clostridium strains described herein can be efficiently prepared, stored, formulated for oral administration, and advantageously used in the prevention and/or treatment of infectious diseases, such as COVID-19.

SARS-COV-2 IMMUNOASSAY METHOD AND IMMUNOASSAY KIT

Resumen de: US2024255505A1

The present invention provides an immunoassay method for assaying SARS-CoV-2 in a biological sample, including using two types of monoclonal antibodies or antibody fragments thereof that bind to a peptide fragment having 30 or less consecutive amino acids in a nucleocapsid protein of SARS-CoV-2, wherein the two types of monoclonal antibodies or antibody fragments thereof recognize different epitopes

METHOD FOR DETECTING ANTI-SARS-COV-2 ANTIBODY, CHIMERIC PROTEIN, POLYNUCLEOTIDE, EXPRESSION VECTOR, HOST CELL, METHOD FOR PRODUCING CHIMERIC PROTEIN, AND REAGENT

Resumen de: US2024255507A1

Disclosed is a method for detecting an anti-SARS-CoV-2 antibody, the method comprising: detecting an antibody against a chimeric protein comprising an amino acid sequence of a receptor binding region of SARS-CoV-2 and an amino acid sequence of a receptor binding region of a coronavirus belonging to Nobecovirus subgenus in a specimen obtained from a subject using the chimeric protein, the chimeric protein being a protein represented by (i) a protein comprising an amino acid sequence set forth in SEQ ID NO: 1 or 2; or (ii) a protein comprising an amino acid sequence having 80% or more of identity to the amino acid sequence set forth in SEQ ID NO: 1 or 2 and binding to an antibody that recognizes the receptor binding region of SARS-CoV-2.

COMPOSITIONS CONTAINING VERTEPORFIN, RIBAVIRIN, GEMCITABINE, OR COMBINATIONS THEREOF AND METHODS OF USE FOR TREATING COVID-19, CANCER, OR NON CANCER DISEASES

Resumen de: US2024252525A1

Disclosed are pharmaceutical formulations and methods using Verteporfin, Ribavirin, and/or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and/or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and/or combinations thereof as an inhaled dry powder treatment for COVID-19 and/or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and/or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions. The administering of Verteporfin alone or in combination with Ribavirin and Gemcitabine may be followed or co-administered with photodynamic and/or sonodynamic therapy (PDT/SDT).

Products of manufacture and methods for treating, ameliorating or preventing coronavirus infection

Resumen de: AU2024204821A1

PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION Abstract Therapeutic agents, combination therapies, and methods for the treatment of coronavirus infections and associated diseases, particularly COVID-19, are provided. The provided therapeutics include oseltamivir, lopinavir, ritonavir, chloroquine or hydroxychloroquine, azithromycin, clarithromycin, doxycycline, ivermectin, and combinationsthereof.

OMICRON CORONAVIRUS VACCINE CONSTRUCTS AND METHODS OF MAKING AND USING SAME

Resumen de: AU2023216258A1

Provided herein are adenoviral vectors encoding spike protein variants of SARS-CoV2 coronavirus, and compositions comprising the vectors. Also provided are methods of prevention and treatment of SARS-CoV2 using the compositions provided.

PROTEIN ANTIGEN-BINDING MOLECULES

Resumen de: US2024254204A1

The present disclosure provides antigen-binding molecule capable of binding to a sarbecovirus spike protein from two or more different sarbecovirus. Nucleic acids, expression 5 vectors, and cells for making and using the same. In particular antigen-binding molecules such as neutralising antibodies capable of inhibiting interaction between the sarbecovirus spike protein and ACE2, thus behaving as antagonists of infection of ACE2-expressing cells by the sarbecovirus. Antigen-binding molecules described herein are provided with a combination of advantageous properties over known SARS-COV-2 antibodies.

ANTIBODY-BASED ANTIVIRUS COMPOSITIONS AND METHODS OF USE

Resumen de: US2024254203A1

Provided herein are antibody-based antiviruses comprising a fusion protein that comprises a transmembrane polypeptide and an antibody which binds to a surface protein of a virus, wherein the fusion protein is expressed at a valency of at least about 10 copies on a surface of the antivirus, and wherein the antibody neutralizes the virus when expressed within the fusion protein on the surface of the antivirus but does not neutralize the virus when expressed as an isolated antibody. Further provided herein are antibody-based antiviruses for treating a viral infection (e.g., SARS-COV-2).

SARS-CoV-2 TIS-L TIS-L targeting Antiviral Antisense Oligonucleotide with ability to inhibit viral replication of SARS-CoV-2

Resumen de: KR102690306B1

본 발명은 SARS-CoV-2 증식을 억제하는 TIS-L 표적 안티센스 올리고뉴클레오타이드 및 이의 항 바이러스 용도에 관한 것이다. 본 발명에 따른 TIS-L 표적 안티센스 올리고뉴클레오타이드는 구조가 간단하여 대량 생산이 용이하고, 원형주 및 다양한 변형주 바이러스에서 적은 용량으로도 90% 이상의 항바이러스 효능을 나타내는 바, COVID-19 치료제 개발에 유용하게 활용될 수 있다.

LLAMA-DERIVED NANOBODIES BINDING THE SPIKE PROTEIN OF NOVEL CORONAVIRUS SARS-COV-2 WITH NEUTRALIZING ACTIVITY AND APPLICATION THEREOF

Resumen de: US2024254202A1

This disclosure is related to llama-derived nanobodies of which the corresponding sequences are provided, corresponding to the variable domain (VHH) of llama heavy chain antibodies recognizing epitopes of the Spike protein of SARS-COV-2, some of them, directed to the receptor binding domain, RBD. The nanobodies disclosed herein have important scientific significance and application prospects, they can be labeled or fused with fluorochromes and enzymes to be used as reagents for immunodetection of the virus. Most importantly, the disclosed nanobodies can be used in the development of a bio-drug for the prevention and clinical treatment of infection and diseases caused by SARS-COV-2.

Anti-BAFF Antibodies for use in a Method of Treatment of Long Covid and/or Post-Acute Sequelae SARS-CoV-2 Infection (PASC)

Resumen de: US2024254247A1

The present disclosure relates to a B lymphocyte Stimulator (BlyS; B-cell activating factor; BAFF) antagonist for use in the treatment of Long Covid and/or post-acute sequelae SARS-COV-2 infection (PASC). Also disclosed is a BlyS antagonist for use in the treatment of an autoimmune condition induced following a viral infection. Such autoimmune conditions may be chronic, such as Long Covid. Also provided is a method for the treatment of an autoimmune condition induced following a viral infection comprising administering to a subject in need thereof a therapeutically effective amount of a BlyS antagonist.

SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE

Resumen de: AU2022349251A1

The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Compositions described herein include lipid carriers, optionally including an inorganic particle, capable of admixing with nucleic acids. Methods of using the compositions as a COVID-19 vaccine for the treatment of a coronavirus infection are also provided.

RECOMBINANT VACCINE AGAINST COVID-19 TO PRODUCE CELLULAR RESPONSE IN INDIVIDUALS WITH PRE-EXISTING IMMUNITY

Resumen de: CA3230865A1

A recombinant vaccine is described, which comprises an active Newcastle disease viral vector (NDV) having inserted an exogenous nucleotide sequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), without adjuvant, capable of generating a significant cellular response in T cells (CD4+ or CD8+) when stimulated with the S protein of the SARS-CoV-2 virus or proteins derived from it in individuals with previous immunity.

CORONAVIRUS VACCINE

Resumen de: ZA202210524B

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. These methods and agents are, in particular, useful for the prevention or treatment of coronavirus infection. Administration of RNA disclosed herein to a subject can protect the subject against coronavirus infection. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen. Administering to the subject RNA encoding vaccine antigen may provide (following expression of the RNA by appropriate target cells) vaccine antigen for inducing an immune response against vaccine antigen (and disease-associated antigen) in the subject. In December 2019, a pneumonia outbreak of unknown cause occurred in Wuhan, China and it became clear that a novel coronavirus (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) was the underlying cause. The genetic sequence of SARS-CoV-2 became available to the WHO and public (MN908947.3) and the virus was categorized into the betacor

COMPOSITION FOR TREATING CORONAVIRUS DISEASE 2019 (COVID-19) CONTAINING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ANTIVIRAL AGENT AS ACTIVE INGREDIENTS

Resumen de: EP4406540A1

The present invention relates to a composition for treating coronavirus infection-19 (COVID-19), comprising taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof and an antiviral agent as active ingredients, it was confirmed that clinical symptoms were cured in patients with COVID-19 pneumonia who were administered a combination of a pharmaceutically acceptable salt of taurodeoxycholic acid as an inflammasome inhibitor and an antiviral agent, and thus this combination of taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an inflammasome inhibitor and an antiviral agent, holds promise as active ingredients in compositions for the prevention or treatment of lower respiratory tract infectious diseases, including COVID-19.

METHOD AND DEVICE FOR INACTIVATING NOVEL CORONAVIRUS

Resumen de: EP4406561A1

Provided are a new coronavirus inactivation method and a new coronavirus inactivation device that are capable of quick inactivation, are safe, and are practical.The new coronavirus inactivation device is a device for inactivating new coronavirus SARS-CoV-2 by singlet oxygen, the device including: a contactor configured to bring an aqueous rose bengal solution and air containing the new coronavirus SARS-CoV-2 into contact with each other in a state where light is applied to the aqueous rose bengal solution, wherein the aqueous rose bengal solution has a concentration of not less than 10 µM and not greater than 50 µM, and the light applied to the aqueous rose bengal solution has an illuminance of not less than 500 lux and not greater than 8000 lux.

RIBONUCLEOSIDE ANALOGUES AGAINST -SARS-COV-2

Resumen de: WO2023046900A1

The invention relates to nucleoside derivatives of formula (I), wherein R has the same meaning as that defined in the claims and the description. The present invention also relates to pharmaceutical compositions comprising such compounds and to uses of such compounds and compositions for the treatment or prevention of viral infections, more in particular infections caused by RNA virus, such as coronavirus infections.

Method of determining the level of risk of severe COVID-19 disease in a patient

Resumen de: PL446346A1

Ujawniono sposób badania obecności dwóch polimorfizmów genetycznych, których występowanie istotnie modyfikuje przebieg choroby COVID-19, sposób ten stanowi nowe narzędzie w ochronie populacji przed chorobą COVID-19.

Kit and method for detecting infection, especially with SARS-CoV-2 virus, using in situ hybridization

Resumen de: PL443616A1

Zestaw do wykrywaniu zakażenia, zwłaszcza wirusem SARS-CoV-2, przy użyciu hybrydyzacji in situ, charakteryzuje się tym, że zawiera: - oligonukleotydową sondę hybrydyzacyjną specyficzną wobec genomu patogenu wywołującego zakażenie lub produktu transkrypcji tego genomu, zwłaszcza genu wirusa SARS-CoV-2 lub produktu transkrypcji tego genu wybranego spośród: E1, E2, E3, N1, N2, N3, ORFlab1, ORFlab2, ORFlab3 oraz produktów transkrypcji tych genów, - znakowaną, zwłaszcza fluorescencyjnie, sondę hybrydyzacyjną, przy czym wspomniana oligonukleotydowa sonda hybrydyzacyjna, specyficzna wobec genomu patogenu wywołującego zakażenie lub produktu transkrypcji tego genomu, posiada na obydwu swoich końcach sekwencję nukleotydową komplementarną do znakowanej sondy hybrydyzacyjnej. Przedmiotem zgłoszenia jest również sposób wykrywaniu zakażenia wirusem SARS-CoV-2 przy użyciu hybrydyzacji in situ.

How to assess the risk of severe COVID-19

Resumen de: PL443593A1

Przedmiotem zgłoszenia jest sposób oceny ryzyka ciężkiego przebiegu COVID-19, w którym dokonuje się oceny poziomu pozawątrobowej witaminy K1 w krwi, osoczu lub surowicy, przy czym jeśli poziom witaminy K1 jest niższy niż 1,0 nmol/dm<3>, to uznaje się, że występuje wysokie ryzyko ciężkiego przebiegu COVID-19.

AGENT FOR TREATING INFECTIOUS DISEASES AGAINST MUTANT VIRUSES OF NOVEL CORONAVIRUS

Resumen de: US2024245679A1

This agent for treating coronavirus infectious diseases caused by mutant viruses of SARS-COV-2 contains, as an active ingredient, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof.

INTRANASAL ADMINSTRATION OF CANNABIGEROL, CBDa, CBGa, & UNCARIA TOMENTOSA HYDROALCOHOLIC EXTRACT COMPOUNDS EMULSIFIED IN SALINE HOMOGENOUS SOLUTION FOR INTRANASAL ADMINISTRATION

Resumen de: US2024245744A1

The therapeutic product invention states to the use of quantified solutions containing natural compounds of cannabidiol, CBDa, cannabigerol, CBGa combined with Uncaria tomentosas' hydroalcoholic extracts emulsified in saline solution in homogenous mixture administered intranasally. A natural respiratory immune booster with mechanisms against respiratory viruses and foreign substances (e.g. SARS-Cov-2 spike protein, bacterial, allergen) including; inhibition, reduction, blockage of cellular entry, and encapsulation and expulsion with minute impact of variant lineage. By induction of the interferon pathway both directly and indirectly following activation of the host immune response to viral pathogen, suppressing cytokine activation in response to viral infection, as well as blocks viral replication after entry into cells. Attaching to viral protein, mechanically inhibiting the SARS-COV-2 enzyme 3CLpro and disrupts the interface of the receptor-binding domain of angiotensin-converting enzyme 2 (RBD-ACE-2) as well as the SARS-COV-2 spike glycoprotein.

USE OF GAMMA PRIME FIBRINOGEN AS A BIOMARKER IN THE ASSESSMENT FOR TREATMENT OF COVID-19 INFECTIONS AND LONG COVID-19

Resumen de: WO2024154045A1

A method is provided for treating a subject with an alternative therapeutic agent to heparin including a non-heparin anticoagulant, wherein the subject has been infected with COVID-19 or has symptoms of long COVID-19 post infection with COVID-19, the method comprising the steps of: obtaining or having obtained a sample from the subject, determining levels of GPF in the sample are above a reference range, and administering the alternative therapeutic agent to the subject if the GPF levels in the sample indicate the subject is heparin resistant, and wherein the alternative therapeutic agent preferably prevents activation of thrombin or reduces levels of active thrombin.

ANTIBODY SPECIFICALLY BINDING TO IL-10 RECEPTOR AND USE THEREOF

Resumen de: WO2024154958A1

The present invention relates to an antibody specifically binding to an IL-10 receptor and use thereof. The antibody targets IL-10 signaling and has an excellent effect of suppressing cytokine storm and excessive inflammation in severe inflammatory infectious diseases, and in particular, can be effectively used in suppressing inflammatory responses in severe SARS-CoV-2 infection and fatal SFTSV infection.

ANTIVIRAL PRODRUGS, INTERMEDIATE- AND LONG-ACTING FORMULATIONS AND METHODS

Resumen de: AU2023213682A1

Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.

REAL-TIME BREATH ANTIGEN DETECTION SYSTEM AND METHOD THEREOF

Resumen de: AU2023213096A1

The invention relates to a system for antigen detection comprising a first container configured to collect aerosols out of exhaled air of a human and a second container suitable for a solvent, wherein nanoparticles are dissolved in the solvent and the nanoparticles are linked to antibodies, further wherein a change of optical properties of the solvent is detectable upon contact between the antibodies and matching antigens. Here, a person can exhale air into the first container, and the aerosols exhaled in the air stick in a filter on one side of the first container. Thereupon, the first container is incooperable in the second container, in which a solvent with nanoparticles dissolved therein and antibodies coupled thereto are located. The incooperability, in particular a shuttling stroke motion, flushes the aerosols into the solvent. If antigens matching the antibodies are present on the aerosols, the nanoparticles agglomerate around the antigen, changing the optical properties of the solvent, which is irradiated by a light source and detectable by a light sensor. In further aspects, the invention relates to a method using the system according to the invention. The invention further relates to corresponding medical uses and therapeutic methods of administering a prevention of a medical condition associated with a SARS Coronavirus, in addition to diagnostic uses and methods.

RECOMBINANT NEWCASTLE DISEASE VIRUSES AND IMMUNOGENIC COMPOSITIONS FOR USE IN PREVENTING COVID-19

Resumen de: AU2023231285A1

Described herein are recombinant Newcastle disease viruses ("NDVs") comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotide sequence encoding a protein comprising a SARS-CoV-2 spike protein or portion thereof. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 spike protein ectodomain and NOV F protein transmembrane and cytoplasmic domains. Further, described herein are immunogenic compositions comprising a recombinant NDV(s). The recombinant NDVs and immunogenic compositions are useful for the immunizing against SARS-CoV-2 as well as the prevention of CO VID-19.

SARS-COV-2 DETECTION USING N GENE PROBE.

Resumen de: MX2023001061A

The present invention discloses a susceptible method for the detection of the SARS-CoV-2 virus that allows the detection of asymptomatic subjects and mildly symptomatic subjects from a self-collected mouthwash and saliva (MWS) biological sample, thereby eliminating the possible exposure and infection of health personnel who traditionally take nasopharyngeal and oropharyngeal swab samples. The protocol comprises a self-collected mouthwash and saliva sample, virus inactivation, and primers/probes for the virus's N gene region and the endogenous human RPP30 gene. The sensitivity of the method of the present invention allows early detection of the virus (asymptomatic subjects) to establish an epidemiological surveillance system in different population groups.

PORTABLE HYPERBARIC OXYGEN (PHBO) HOOD FOR COVID-19 PATIENTS

Resumen de: US2024245875A1

A portable hyperbaric oxygen (PHBO) hood system includes a main hood, a neck sleeve configured to be disposed below the main hood, a pump system configured to control a pressure in the main hood to create hyperbaric environment in the PHBO hood system, and an intelligent controller. The pump system includes a pump and a flow line configured to supply oxygen to the main hood via the pump. The intelligent controller is configured to receive an oxygen saturation value of a patient, receive an oxygen concentration value of the flow line, determine a target pressure of the main hood based on the oxygen saturation value and the oxygen concentration value, and control the pump system to change the pressure of the main hood to the target pressure.

SARS-COV-2 RBD CONSTRUCTS

Resumen de: US2024247033A1

The present invention relates to glycan-masked and membrane-tethered SARS-CoV-2 RBD vaccine constructs and methods for making and administering the same. The present invention also encompasses a general vaccine platform for coronaviruses.

METHODS AND COMPOSITIONS FOR DETECTING SARS-COV2 VIRUS OMICRON, ALPHA, BETA, DELTA, OR GAMMA

Resumen de: US2024247322A1

The present invention concerns methods for detecting SARS-CoV 2 virus omicron, alpha, beta, delta and/or gamma as well as kits for performing such methods.

MEDICATED DIET COMPOSITION FOR TREATING COLD COUGH, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2024153266A1

The present invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a medicated diet composition for treating a cold cough, and a preparation method therefor and the use thereof. The medicated diet composition of the present invention comprises the raw materials in the following parts by mass: 50-100 parts of kumquat, 10-20 parts of fresh ginger, 2-3 parts of Citri reticulatae pericarpium and 5-10 parts of Platycodonis radix. The medicated diet composition of the present invention can quickly improve the symptoms of a cold cough of a SARS-CoV-2 infection, and is particularly suitable for patients with a cold cough of a SARS-CoV-2 infection in regions where drug resources are relatively short, medical resources are relatively poor and the purchase of drugs is relatively difficult.

PREPARATION AND USE OF MRNA VACCINE AND RECOMBINANT PROTEIN SUBUNIT VACCINE AGAINST SARS-COV-2 OR MUTANT

Resumen de: WO2024152845A1

Provided in the present invention is a recombinant protein vaccine and/or an mRNA vaccine for preventing and/or treating infections of SARS-CoV-2 or a mutant thereof, and particularly provided is a method of using the mRNA vaccine and the recombinant protein vaccine. The vaccine can induce the generation of an antibody response and a cellular immune response in vivo to block the binding of the S protein of SARS-CoV-2 to the ACE2 receptor of host cells, so that the host resists coronavirus infections.

MEDICATED DIET COMPOSITION FOR TREATING HEAT COUGH, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2024153265A1

A medicated diet composition for treating a heat cough, prepared from the raw materials in the following parts by mass: 50-100 parts of kumquat, 30-50 parts of Eleocharis dulcis, 5-10 parts of Glehniae radix and 5-10 parts of Platycodonis radix. The medicated diet composition can improve the symptoms of a heat cough of a SARS-CoV-2 infection.

USE OF CPG ADJUVANT IN PREPARATION OF NOVEL CORONAVIRUS VACCINE

Resumen de: WO2024152998A1

Use of a CpG adjuvant in the preparation of a novel coronavirus vaccine. Provided is a composite adjuvant, comprising the CpG adjuvant and an A1 adjuvant. The nucleotide sequence of the CpG adjuvant is SEQ ID NOs: 1-5. Provided is a novel coronavirus vaccine, consisting of a novel coronavirus antigen, and the CpG adjuvant and the A1 adjuvant in a first aspect. Provided is a composition (vaccine) for stimulating or eliciting an immune response against SARS-CoV-2. The immune response includes, but is not limited to, an immune response that generates a neutralizing antibody against SARS-CoV-2 and is biased towards Thl. CpGODN is a fully phosphorothioated oligodeoxynucleotide containing non-methylated CG dinucleotide (CpG) linked by phosphorus (p), and has an immunostimulatory effect.

PROTEIN AND VACCINE FOR RESISTING INFECTION FROM SARS-COV-2 OMICRON MUTANT STRAIN AND SUBTYPE THEREOF

Resumen de: WO2024152844A1

The present invention relates to the field of medicines, and relates to a protein and vaccine for resisting infection from a SARS-CoV-2 Omicron mutant strain and a subtype thereof. In order to solve the problem of lack of drugs for effective prevention and treatment for infections from the SARS-CoV-2 Omicron mutant strain and the subtype thereof, the present invention provides the protein and the vaccine for resisting infection from the SARS-CoV-2 Omicron mutant strain and the subtype thereof. The vaccine is optimally designed on the basis of an RBD sequence in an S protein of the SARS-CoV-2 Omicron mutant strain and substrains BA.4/5, BQ.1.1, and XBB.1.5, can help a host to resist a coronavirus infection, and particularly has a relatively good prevention and treatment effect on a cross infection caused by a SARS-CoV-2 Omicron mutant strain and subtype viruses thereof.

ANTISENSE MOLECULES AND THEIR USES FOR THE TREATMENT OF CORONAVIRUS INFECTION, IN PARTICULAR THE TREATMENT OF COVID-19 RELATED TO SARS-COV-2 INFECTION

Resumen de: WO2024153586A1

The present invention relates to a new antisense oligonucleotide, a pharmaceutical composition comprising it and their use for preventing or treating infection by coronavirus, especially by SARS-CoV-2 virus which causes the infection disease COVID-19.

SYNTHETIC HUMANIZED LLAMA NANOBODY LIBRARY AND USE THEREOF TO IDENTIFY SARS-COV-2 NEUTRALIZING ANTIBODIES

Resumen de: AU2022345251A1

Methods for producing synthetic single-domain monoclonal antibody libraries using humanized llama nanobody framework sequences, libraries obtainable by the method, as well as antibodies selected from the libraries are described. In particular, synthetic single-domain monoclonal antibodies that specifically bind to the spike protein of SARS-CoV-2 and neutralize SARS-CoV-2 infection are described. Use of the disclosed antibodies for the detection, prophylaxis and treatment of SARS-CoV-2 infection is described.

BUTYROPHILIN (BTN) 3A ACTIVATING ANTIBODIES FOR USE IN METHODS FOR TREATING INFECTIOUS DISORDERS.

Resumen de: MX2024005190A

The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.

ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF IN THE MEDICAL FIELD

Resumen de: WO2023042235A1

The present invention relates to antibodies against SARS-CoV-2 and uses thereof in the medical field for the prevention and treatment of SARS-CoV-2 infection and COVID-19 disease.

NEW COMBINATION DRUG FOR TREATING CORONAVIRUS INFECTIONS, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Nº publicación: EP4403177A1 24/07/2024

Solicitante:

ONEGLOBE HOLDINGS LTD [HK]
Oneglobe Holdings Limited

Resumen de: EP4403177A1

The present invention provides a new combinatorial drug or a new pharmaceutical composition comprising nitazoxanide, atovaquone and/or ribavirin, and their use for the treatment or prevention of coronavirus infections, particularly the use for the treatment or prevention of infections caused by SARS-CoV-2 and mutants thereof.